EP1185863A2 - Un systeme de criblage a base de cellules - Google Patents

Un systeme de criblage a base de cellules

Info

Publication number
EP1185863A2
EP1185863A2 EP00937548A EP00937548A EP1185863A2 EP 1185863 A2 EP1185863 A2 EP 1185863A2 EP 00937548 A EP00937548 A EP 00937548A EP 00937548 A EP00937548 A EP 00937548A EP 1185863 A2 EP1185863 A2 EP 1185863A2
Authority
EP
European Patent Office
Prior art keywords
cell
cells
distribution
protein
luminescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00937548A
Other languages
German (de)
English (en)
Inventor
Keith Olson
Oleg Lapets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellomics Inc
Original Assignee
Cellomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellomics Inc filed Critical Cellomics Inc
Publication of EP1185863A2 publication Critical patent/EP1185863A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition

Definitions

  • This invention is in the field of fluorescence-based cell and molecular biochemical assays for drug discovery.
  • Drug discovery is a long, multiple step process involving identification of specific disease targets, development of an assay based on a specific target, validation of the assay, optimization and automation of the assay to produce a screen, high throughput screening of compound libraries using the assay to identify "hits", hit validation and hit compound optimization.
  • the output of this process is a lead compound that goes into pre-clinical and, if validated, eventually into clinical trials.
  • the screening phase is distinct from the assay development phases, and involves testing compound efficacy in living biological systems.
  • drug discovery is a slow and costly process, spanning numerous years and consuming hundreds of millions of dollars per drug created.
  • Genomic methods such as subtraction hybridization and RADE (rapid amplification of differential expression) can be used to identify genes that are up or down regulated in a disease state model. However, identification and validation still proceed down the same pathway.
  • Some proteomic methods use protein identification (global expression arrays, 2D electrophoresis, combinatorial libraries) in combination with reverse genetics to identify candidate genes of interest.
  • Such putative "disease associated sequences" or DAS isolated as intact cDNA are a great advantage to these methods, but they are identified by the hundreds without providing any information regarding type, activity, and distribution of the encoded protein.
  • GFP modified green fluorescent protein
  • GFP GFP-binding protein
  • WO96/23898 relates to methods of detecting biologically active substances affecting intracellular processes by utilizing a GFP construct having a protein kinase activation site.
  • This patent, and all other patents referenced in this application are incorporated by reference in their entirety Numerous references are related to GFP proteins in biological systems.
  • WO 96/09598 describes a system for isolating cells of interest utilizing the expression of a GFP like protein.
  • WO 96/27675 describes the expression of GFP in plants.
  • WO 95/21191 describes modified GFP protein expressed in transformed organisms to detect mutagenesis.
  • Patents 5,401,629 and 5,436,128 describe assays and compositions for detecting and evaluating the intracellular transduction of an extracellular signal using recombinant cells that express cell surface receptors and contain reporter gene constructs that include transcriptional regulatory elements that are responsive to the activity of cell surface receptors. Performing a screen on many thousands of compounds requires parallel handling and processing of many compounds and assay component reagents. Standard high throughput screens (“HTS”) use mixtures of compounds and biological reagents along with some indicator compound loaded into arrays of wells in standard microtiter plates with 96 or 384 wells. The signal measured from each well, either fluorescence emission, optical density, or radioactivity, integrates the signal from all the material in the well giving an overall population average of all the molecules in the well.
  • HTS high throughput screens
  • SAIC Science Applications International Corporation 130 Fifth Avenue, Seattle, WA. 98109
  • This system uses a CCD camera to image the whole area of a 96 well plate. The image is analyzed to calculate the total fluorescence per well for all the material in the well.
  • Molecular Devices, Inc. (Sunnyvale, CA) describes a system (FLIPR) which uses low angle laser scanning illumination and a mask to selectively excite fluorescence within approximately 200 microns of the bottoms of the wells in standard 96 well plates in order to reduce background when imaging cell monolayers.
  • FLIPR Fluorescence-Coupled Devices
  • This system uses a CCD camera to image the whole area of the plate bottom. Although this system measures signals originating from a cell monolayer at the bottom of the well, the signal measured is averaged over the area of the well and is therefore still considered a measurement of the average response of a population of cells. The image is analyzed to calculate the total fluorescence per well for cell-based assays.
  • Fluid delivery devices have also been incorporated into cell based screening systems, such as the FLIPR system, in order to initiate a response, which is then observed as a whole well population average response using a macro-imaging system.
  • various high-content screens (“HCS”) have been developed to address the need for more detailed information about the temporal-spatial dynamics of cell constituents and processes.
  • High-content screens automate the extraction of multicolor fluorescence information derived from specific fluorescence-based reagents incorporated into cells (Giuliano and Taylor (1995), Curr. Op. Cell Biol. 7:4; Giuliano et al. (1995) Ann. Rev. Biophys. Biomol. Struct. 24:405).
  • the types of biochemical and molecular information now accessible through fluorescence-based reagents applied to cells include ion concentrations, membrane potential, specific translocations, enzyme activities, gene expression, as well as the presence, amounts and patterns of metabolites, proteins, lipids, carbohydrates, and nucleic acid sequences (DeBiasio et al., (1996) Mol. Biol. Cell. 7:1259;Giuliano et al., (1995) Ann. Rev. Biophys. Biomol. Struct. 24:405; Heim and Tsien, (1996) Curr. Biol. 6:178).
  • High-content screens can be performed on either fixed cells, using fluorescently labeled antibodies, biological ligands, and/or nucleic acid hybridization probes, or live cells using multicolor fluorescent indicators and "biosensors.”
  • the choice of fixed or live cell screens depends on the specific cell-based assay required.
  • Fixed cell assays are the simplest, since an array of initially living cells in a microtiter plate format can be treated with various compounds and doses being tested, then the cells can be fixed, labeled with specific reagents, and measured. No environmental control of the cells is required after fixation. Spatial information is acquired, but only at one time point. The availability of thousands of antibodies, ligands and nucleic acid hybridization probes that can be applied to cells makes this an attractive approach for many types of cell-based screens. The fixation and labeling steps can be automated, allowing efficient processing of assays. Live cell assays are more sophisticated and powerful, since an array of living cells containing the desired reagents can be screened over time, as well as space.
  • the system consists of an epifiuorescence inverted microscope with a motorized stage, video camera, image intensifier, and a microcomputer with a PC- Vision digitizer.
  • Turbo Pascal software controls the stage and scans the plate taking multiple images per well.
  • the software calculates total fluorescence per well, provides for daily calibration, and configures easily for a variety of tissue culture plate formats. Thresholding of digital images and reagents which fluoresce only when taken up by living cells are used to reduce background fluorescence without removing excess fluorescent reagent.
  • the instant invention provides systems, methods, and screens that combine high throughput screening (HTS) and high content screening (HCS) that significantly improve target validation and candidate optimization by combining many cell screening formats with fluorescence-based molecular reagents and computer-based feature extraction, data analysis, and automation, resulting in increased quantity and speed of data collection, shortened cycle times, and, ultimately, faster evaluation of promising drug candidates.
  • HTS high throughput screening
  • HCS high content screening
  • the instant invention also provides for miniaturizing the methods, thereby allowing increased throughput, while decreasing the volumes of reagents and test compounds required in each assay.
  • the present invention relates to a method for analyzing cells comprising
  • the method rapidly determines the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions.
  • the array of locations may be a microtiter plate or a microchip which is a microplate having cells in an array of locations.
  • the method includes computerized means for acquiring, processing, displaying and storing the data received.
  • the method further comprises automated fluid delivery to the arrays of cells.
  • the information obtained from high throughput measurements on the same plate are used to selectively perform high content screening on only a subset of the cell locations on the plate.
  • a cell screening system comprises: • a high magnification fluorescence optical system having a microscope objective, • an XY stage adapted for holding a plate containing an array of cells and having a means for moving the plate for proper alignment and focusing on the cell arrays;
  • a digital camera • a light source having optical means for directing excitation light to cell arrays and a means for directing fluorescent light emitted from the cells to the digital camera; and
  • a computer means for receiving and processing digital data from the digital camera
  • the computer means includes a digital frame grabber for receiving the images from the camera, a display for user interaction and display of assay results, digital storage media for data storage and archiving, and a means for control, acquisition, processing and display of results.
  • the cell screening system further comprises a computer screen operatively associated with the computer for displaying data.
  • the computer means for receiving and processing digital data from the digital camera stores the data in a bioinformatics data base.
  • the cell screening system further comprises a reader that measures a signal from many or all the wells in parallel.
  • the cell screening system further comprises a mechanical-optical means for changing the magnification of the system, to allow changing modes between high throughput and high content screening.
  • the cell screening system further comprises a chamber and control system to maintain the temperature, CO concentration and humidity surrounding the plate at levels required to keep cells alive.
  • the cell screening system utilizes a confocal scanning illumination and detection system.
  • a machine readable storage medium comprising a program containing a set of instructions for causing a cell screening system to execute procedures for defining the distribution and activity of specific cellular constituents and processes.
  • the cell screening system comprises a high magnification fluorescence optical system with a stage adapted for holding cells and a means for moving the stage, a digital camera, a light source for receiving and processing the digital data from the digital camera, and a computer means for receiving and processing the digital data from the digital camera.
  • Preferred embodiments of the machine readable storage medium comprise programs consisting of a set of instructions for causing a cell screening system to execute the procedures set forth in Figures 9, 11, 12, 13, 14 or 15.
  • Another preferred embodiment comprises a program consisting of a set of instructions for causing a cell screening system to execute procedures for detecting the distribution and activity of specific cellular constituents and processes.
  • the cellular processes include, but are not limited to, nuclear translocation of a protein, cellular hypertrophy, apoptosis, and protease-induced translocation of a protein.
  • a variety of automated cell screening methods and kits are provided, including screens to identify compounds that affect transcription factor activity, protein kinase activity, cell morphology, microtubule structure, apoptosis, receptor intemalization, protease-induced translocation of a protein, and peroxisoim proliferation and distribution.
  • Figure 1 shows a diagram of the components of the cell-based scanning system.
  • Figure 2 shows a schematic of the microscope subassembly.
  • Figure 3 shows the camera subassembly.
  • Figure 4 illustrates cell scanning system process
  • Figure 5 illustrates a user interface showing major functions to guide the user.
  • Figure 6 is a block diagram of the two platform architecture of the Dual Mode System for Cell Based Screening in which one platform uses a telescope lens to read all wells of a microtiter plate and a second platform that uses a higher magnification lens to read individual cells in a well.
  • Figure 7 is a detail of an optical system for a single platform architecture of the Dual
  • FIG. 8 is an illustration of the fluid delivery system for acquiring kinetic data on the
  • Figure 9 is a flow chart of processing step for the cell-based scanning system.
  • Figure 10 A-J illustrates the strategy of the Nuclear Translocation Assay.
  • Figure 11 is a flow chart defining the processing steps in the Dual Mode System for
  • Figure 12 is a flow chart defining the processing steps in the High Throughput mode of the System for Cell Based Screening.
  • Figure 13 is a flow chart defining the processing steps in the High Content mode of the
  • Figure 14 is a flow chart defining the processing steps required for acquiring kinetic data in the High Content mode of the System for Cell Based Screening.
  • Figure 15 is a flow chart defining the processing steps performed within a well during the acquisition of kinetic data.
  • Figure 16 is an example of data from a known inhibitor of translocation.
  • Figure 17 is an example of data from a known stimulator of translocation.
  • Figure 18 illustrates data presentation on a graphical display.
  • Figure 19 is an illustration of the data from the High Throughput mode of the System for Cell Based Screening, an example of the data passed to the High Content mode, the data acquired in the high content mode, and the results of the analysis of that data.
  • Figure 20 shows the measurement of a drug-induced cytoplasm to nuclear translocation.
  • Figure 21 illustrates a graphical user interface of the measurement shown in Figure 20.
  • Figure 22 illustrates a graphical user interface, with data presentation, of the measurement shown in Fig. 20.
  • Figure 23 is a graph representing the kinetic data obtained from the measurements depicted in Fig. 20.
  • Figure 24 details a high-content screen of drug-induced apoptosis.
  • Luminescent probes that have high affinity for specific cellular constituents including specific organelles or molecules. These probes can either be small luminescent molecules or fluorescently tagged macromolecules used as "labeling reagents", “environmental indicators”, or “biosensors.”
  • Labeling reagents include, but are not limited to, luminescently labeled macromolecules including fluorescent protein analogs and biosensors, luminescent macromolecular chimeras including those formed with the green fluorescent protein and mutants thereof, luminescently labeled primary or secondary antibodies that react with cellular antigens involved in a physiological response, luminescent stains, dyes, and other small molecules. Markers of cellular translocations. Luminescently tagged macromolecules or organelles that move from one cell domain to another during some cellular process or physiological response. Translocation markers can either simply report location relative to the markers of cellular domains or they can also be "biosensors" that report some biochemical or molecular activity as well. Biosensors.
  • Macromolecules consisting of a biological functional domain and a luminescent probe or probes that report the environmental changes that occur either internally or on their surface.
  • a class of luminescently labeled macromolecules designed to sense and report these changes have been termed "fluorescent-protein biosensors".
  • the protein component of the biosensor provides a highly evolved molecular recognition moiety.
  • a fluorescent molecule attached to the protein component in the proximity of an active site transduces environmental changes into fluorescence signals that are detected using a system with an appropriate temporal and spatial resolution such as the cell scanning system of the present invention. Because the modulation of native protein activity within the living cell is reversible, and because fluorescent-protein biosensors can be designed to sense reversible changes in protein activity, these biosensors are essentially reusable.
  • DAS Disease associated sequences
  • High content screening can be used to measure the effects of drugs on complex molecular events such as signal transduction pathways, as well as cell functions including, but not limited to, apoptosis, cell division, cell adhesion, locomotion, exocytosis, and cell-cell communication.
  • Multicolor fluorescence permits multiple targets and cell processes to be assayed in a single screen. Cross-correlation of cellular responses will yield a wealth of information required- for target validation and lead optimization.
  • a cell screening system comprising a high magnification fluorescence optical system having a microscope objective, an XY stage adapted for holding a plate with an array of locations for holding cells and having a means for moving the plate to align the locations with the microscope objective and a means for moving the plate in the direction to effect focusing; a digital camera; a light source having optical means for directing excitation light to cells in the array of locations and a means for directing fluorescent light emitted from the cells to the digital camera; and a computer means for receiving and processing digital data from the digital camera wherein the computer means includes: a digital frame grabber for receiving the images from the camera, a display for user interaction and display of assay results, digital storage media for data storage and archiving, and means for control, acquisition, processing and display of results.
  • FIG. 1 is a schematic diagram of a preferred embodiment of the cell scanning system.
  • An inverted fluorescence microscope is used ⁇ , such as a Zeiss Axiovert inverted fluorescence microscope which uses standard objectives with magnification of 1 -1 OOx to the camera, and a white light source (e.g. 100W mercury-arc lamp or 75 W xenon lamp) with power supply 2.
  • ⁇ such as a Zeiss Axiovert inverted fluorescence microscope which uses standard objectives with magnification of 1 -1 OOx to the camera, and a white light source (e.g. 100W mercury-arc lamp or 75 W xenon lamp) with power supply 2.
  • a Z-axis focus drive 5 moves the objective in the Z direction for focusing.
  • a joystick 6 provides for manual movement of the stage in the XYZ direction.
  • a high resolution digital camera 7 acquires images from each well or location
  • FIG. 1 is a schematic of one embodiment of the microscope assembly 1 of the invention, showing in more detail the XY stage 3, Z-axis focus drive 5, joystick 6, light source 2, and automation controller 9. Cables to the computer L5 and microscope 16, respectively, are provided.
  • Figure 2 shows a 96 well microtiter plate 17 which is moved on the XY stage 3 in the XY direction. Light from the light source 2 passes through the PC controlled shutter 18 to a motorized filter wheel 19 with excitation filters 20.
  • FIG. 1 shows a schematic drawing of a preferred camera assembly.
  • a digital cable 30 transports digital signals to the computer.
  • the standard optical configurations described above use microscope optics to directly produce an enlarged image of the specimen on the camera sensor in order to capture a high resolution image of the specimen.
  • This optical system is commonly referred to as 'wide field' microscopy.
  • a high resolution image of the specimen can be created by a variety of other optical systems, including, but not limited to, standard scanning confocal detection of a focused point or line of illumination scanned over the specimen (Go et al. 1997, supra), and multi-photon scanning confocal microscopy (Denk et al., 1990, supra), both of which can form images on a CCD detector or by synchronous digitization of the analog output of a photomultiplier tube.
  • a particular cell line or primary cell culture, to take advantage of particular features of those cells.
  • Those skilled in the art of cell culture will recognize that some cell lines are contact inhibited, meaning that they will stop growing when they become surrounded by other cells, while other cell lines will continue to grow under those conditions and the cells will literally pile up, forming many layers.
  • An example of such a cell line is the HEK 293 (ATCC CRL-1573) line.
  • An optical system that can acquire images of single cell layers in multilayer preparations is required for use with cell lines that tend to form layers.
  • the large depth of field of wide field microscopes produces an image that is a projection through the many layers of cells, making analysis of subcellular spatial distributions extremely difficult in layer-forming cells.
  • the very shallow depth of field that can be achieved on a confocal microscope (about one micron), allows discrimination of a single cell layer at high resolution, simplifying the determination of the subcellular spatial distribution.
  • confocal imaging is preferable when detection modes such as fluorescence lifetime imaging are required.
  • the output of a standard confocal imaging attachment for a microscope is a digital image that can be converted to the same format as the images produced by the other cell screening system embodiments described above, and can therefore be processed in exactly the same way as those images.
  • the overall control, acquisition and analysis in this embodiment is essentially the same.
  • the optical configuration of the confocal microscope system is essentially the same as that described above, except for the illuminator and detectors. Illumination and detection systems required for confocal microscopy have been designed as accessories to be attached to standard microscope optical systems such as that of the present invention (Zeiss, Germany). These alternative optical systems therefore can be easily integrated into the system as described above.
  • Figure 4 illustrates an alternative embodiment of the invention in which cell arrays are in microwells 40 on a microplate 4J_, described ion co-pending U.S. Application S/N 08/865,341 , incorporated by reference herein in its entirety.
  • the microplate is 20 mm by 30 mm as compared to a standard 96 well microtiter plate which is 86 mm by 129 mm.
  • the higher density array of cells on a microplate allows the microplate to be imaged at a low resolution of a few microns per pixel for high throughput and particular locations on the microplate to be imaged at a higher resolution of less than 0.5 microns per pixel. These two resolution modes help to improve the overall throughput of the system.
  • the microplate chamber 42 serves as a microfluidic delivery system for the addition of compounds to cells.
  • the microplate 4 . in the microplate chamber 42 is placed in an XY microplate reader 43.
  • Digital data is processed as described above.
  • the small size of this microplate system increases throughput, minimizes reagent volume and allows control of the distribution and placement of cells for fast and precise cell-based analysis.
  • Processed data can be displayed on a PC screen H and made part of a bioinformatics data base 44. This data base not only permits storage and retrieval of data obtained through the methods of this invention, but also permits acquisition and storage of external data relating to cells.
  • Figure 5 is a PC display which illustrates the operation of the software.
  • a high throughput system is directly coupled with the HCS either on the same platform or on two separate platforms connected electronically (e.g. via a local area network).
  • This embodiment of the invention referred to as a dual mode optical system, has the advantage of increasing the throughput of a HCS by coupling it with a HTS and thereby requiring slower high resolution data acquisition and analysis only on the small subset of wells that show a response in the coupled HTS.
  • High throughput 'whole plate' reader systems are well known in the art and are commonly used as a component of an HTS system used to screen large numbers of compounds (Beggs (1997), J. ofBiomolec. Screening 2:71-78; Macaffrey et al., (1996)
  • a two platform architecture in which high throughput acquisition occurs on one platform and high content acquisition occurs on a second platform is provided ( Figure 6). Processing occurs on each platform independently, with results passed over a network interface, or a single controller is used to process the data from both platforms.
  • an exemplified two platform dual mode optical system consists of two light optical instruments, a high throughput platform 60 and a high content platform 65 ⁇ which read fluorescent signals emitted from cells cultured in microtiter plates or microwell arrays on a microplate, and communicate with each other via an electronic connection 64.
  • the high throughput platform 60 analyzes all the wells in the whole plate either in parallel or rapid serial fashion.
  • Those skilled in the art of screening will recognize that there are a many such commercially available high throughput reader systems that could be integrated into a dual mode cell based screening system (Topcount (Packard Instruments, Meriden, CT); Spectramax, Lumiskan (Molecular Devices, Sunnyvale, CA); Fluoroscan (Labsystems, Beverly, MA)).
  • the high content platform 65 as described above, scans from well to well and acquires and analyzes high resolution image data collected from individual cells within a well.
  • the HTS software residing on the system's computer 62, controls the high throughput instrument, and results are displayed on the monitor 6L
  • the HCS software residing on it's computer system 67, controls the high content instrument hardware 65, optional devices (e.g. plate loader, environmental chamber, fluid dispenser), analyzes digital image data from the plate, displays results on the monitor 66 and manages data measured in an integrated database.
  • the two systems can also share a single computer, in which case all data would be collected, processed and displayed on that computer, without the need for a local area network to transfer the data.
  • Microtiter plates are transferred from the high throughput system to the high content system 63 either manually or by a robotic plate transfer device, as is well known in the art (Beggs (1997), supra; Mcaffrey (1996), supra).
  • the dual mode optical system utilizes a single platform system ( Figure 7). It consists of two separate optical modules, an HCS module 203 and an HTS module 209 that can be independently or collectively moved so that only one at a time is used to collect data from the microtiter plate 201.
  • the microtiter plate 201 is mounted in a motorized XN stage so it can be positioned for imaging in either HTS or HCS mode. After collecting and analyzing the HTS image data as described below, the HTS optical module 209 is moved out of the optical path and the HCS optical module 203 is moved into place.
  • the optical module for HTS 209 consists of a projection lens 214. excitation wavelength filter 213 and dichroic mirror 210 which are used to illuminate the whole bottom of the plate with a specific wavelength band from a conventional microscope lamp system (not illustrated). The fluorescence emission is collected through the dichroic mirror 210 and emission wavelength filter 211 by a lens 212 which forms an image on the camera 216 with sensor 215.
  • the optical module for HCS 203 consists of a projection lens 208, excitation wavelength filter 207 and dichroic mirror 204 which are used to illuminate the back aperture of the microscope objective 202. and thereby the field of that objective, from a standard microscope illumination system (not shown).
  • the fluorescence emission is collected by the microscope objective 202. passes through the dichroic mirror 204 and emission wavelength filter 205 and is focused by a tube lens 206 which forms an image on the same camera 216 with sensor 215.
  • the cell screening system further comprises a fluid delivery device for use with the live cell embodiment of the method of cell screening (see below).
  • Figure 8 exemplifies a fluid delivery device for use with the system of the invention.
  • Each syringe 702 is sized according to the volume to be delivered to each well, typically between 1 and 100 ⁇ L.
  • Each syringe is attached via flexible tubing 703 to a similar bank of connectors which accept standard pipette tips 705.
  • the bank of pipette tips are attached to a drive system so they can be lowered and raised relative to the microtiter plate 706 to deliver fluid to each well.
  • the plate is mounted on an X,Y stage, allowing movement relative to the optical system 707 for data collection purposes.
  • This set-up allows one set of pipette tips, or even a single pipette tip, to deliver reagent to all the wells on the plate.
  • the bank of syringe pumps can be used to deliver fluid to 12 wells simultaneously, or to fewer wells by removing some of the tips.
  • the present invention provides a method for analyzing cells comprising providing an array of locations which contain multiple cells wherein the cells contain one or more fluorescent reporter molecules; scanning multiple cells in each of the locations containing cells to obtain fluorescent signals from the fluorescent reporter molecule in the cells; converting the fluorescent signals into digital data; and utilizing the digital data to determine the distribution, environment or activity of the fluorescent reporter molecule within the cells.
  • Microplates may consist of coplanar layers of materials to which cells adhere, patterned with materials to which cells will not adhere, or etched 3-dimensional surfaces of similarly pattered materials.
  • the terms 'well' and 'microweir refer to a location in an array of any construction to which cells adhere and within which the cells are imaged.
  • Microplates may also include fluid delivery channels in the spaces between the wells. The smaller format of a microplate increases the overall efficiency of the system by minimizing the quantities of the reagents, storage and handling during preparation and the overall movement required for the scanning operation. In addition, the whole area of the microplate can be imaged more efficiently, allowing a second mode of operation for the microplate reader as described later in this document.
  • a major component of the new drug discovery paradigm is a continually growing family of fluorescent and luminescent reagents that are used to measure the temporal and spatial distribution, content, and activity of intracellular ions, metabolites, macromolecules, and organelles. Classes of these reagents include labeling reagents that measure the distribution and amount of molecules in living and fixed cells, environmental indicators to report signal transduction events in time and space, and fluorescent protein biosensors to measure target molecular activities within living cells.
  • a multiparameter approach that combines several reagents in a single cell is a powerful new tool for drug discovery.
  • the method of the present invention is based on the high affinity of fluorescent or luminescent molecules for specific cellular components.
  • the affinity for specific components is governed by physical forces such as ionic interactions, covalent bonding (which includes chimeric fusion with protein-based chromophores, fluorophores, and lumiphores), as well as hydrophobic interactions, electrical potential, and, in some cases, simple entrapment within a cellular component.
  • the luminescent probes can be small molecules, labeled macromolecules, or genetically engineered proteins, including, but not limited to green fluorescent protein chimeras.
  • fluorescent reporter molecules that can be used in the present invention, including, but not limited to, fluorescently labeled biomolecules such as proteins, phospholipids and DNA hybridizing probes.
  • fluorescent reagents specifically synthesized with particular chemical properties of binding or association have been used as fluorescent reporter molecules (Barak et al., (1997), J. Biol. Chem. 272:27497-27500; Southwick et al, (1990), Cytometry 11 :418-430; Tsien (1989) in Methods in Cell Biology, Vol. 29 Taylor and Wang (eds.), pp. 127-156).
  • Fluorescently labeled antibodies are particularly useful reporter molecules due to their high degree of specificity for attaching to a single molecular target in a mixture of molecules as complex as a cell or tissue.
  • the luminescent probes can be synthesized within the living cell or can be transported into the cell via several non-mechanical modes including diffusion, facilitated or active transport, signal-sequence-mediated transport, and endocytotic or pinocytotic uptake.
  • Mechanical bulk loading methods which are well known in the art, can also be used to load luminescent probes into living cells (Barber et al. (1996), Neuroscience Letters 207:17-20; Bright et al. (1996), Cytometry 24:226-233; McNeil (1989) in Methods in Cell Biology, Vol. 29, Taylor and Wang (eds.), pp. 153-173).
  • cells can be genetically engineered to express reporter molecules, such as GFP, coupled to a protein of interest as previously described (Chalfie and Prasher U.S. Patent No. 5,491,084; Cubitt et al. (1995), Trends in Biochemical Science 20:448-455).
  • reporter molecules such as GFP
  • the luminescent probes Once in the cell, the luminescent probes accumulate at their target domain as a result of specific and high affinity interactions with the target domain or other modes of molecular targeting such as signal-sequence-mediated transport.
  • Fluorescently labeled reporter molecules are useful for determining the location, amount and chemical environment of the reporter. For example, whether the reporter is in a lipophilic membrane environment or in a more aqueous environment can be determined (Giuliano et al. (1995), Ann. Rev. of Biophysics and Biomolecular Structure 24:405-434; Giuliano and Taylor (1995), Methods in Neuroscience 27:1-16).
  • the pH environment of the reporter can be determined (Bright et al. (1989), J. Cell Biology 104:1019-1033; Giuliano et al. (1987), Anal. Biochem. 167:362-371 ; Thomas et al. (1979), Biochemistry 18:2210-2218).
  • certain cell types within an organism may contain components that can be specifically labeled that may not occur in other cell types.
  • epithelial cells often contain polarized membrane components. That is, these cells asymmetrically distribute macromolecules along their plasma membrane.
  • Connective or supporting tissue cells often contain granules in which are trapped molecules specific to that cell type (e.g., heparin, histamine, serotonin, etc.).
  • Most muscular tissue cells contain a sarcoplasmic reticulum, a specialized organelle whose function is to regulate the concentration of calcium ions within the cell cytoplasm.
  • Many nervous tissue cells contain secretory granules and vesicles in which are trapped neurohormones or neuro transmitters. Therefore, fluorescent molecules can be designed to label not only specific components within specific cells, but also specific cells within a population of mixed cell types.
  • fluorescent reporter molecules exhibit a change in excitation or emission spectra, some exhibit resonance energy transfer where one fluorescent reporter loses fluorescence, while a second gains in fluorescence, some exhibit a loss (quenching) or appearance of fluorescence, while some report rotational movements (Giuliano et al. (1995), Ann. Rev. of Biophysics and Biomol. Structure
  • a preferred embodiment is provided to analyze cells that comprises operator-directed parameters being selected based on the assay being conducted, data acquisition by the cell screening system on the distribution of fluorescent signals within a sample, and interactive data review and analysis.
  • the operator enters information 100 that describes the sample, specifies the filter settings and fluorescent channels to match the biological labels being used and the information sought, and then adjusts the camera settings to match the sample brightness.
  • the software allows selection of various parameter settings used to identify nuclei and cytoplasm, and selection of different fluorescent reagents, identification of cells of interest based on morphology or brightness, and cell numbers to be analyzed per well. These parameters are stored in the system's for easy retrieval for each automated run.
  • the system's interactive cell identification mode simplifies the selection of morphological parameter limits such as the range of size, shape, and intensity of cells to be analyzed.
  • the user specifies which wells of the plate the system will scan and how many fields or how many cells to analyze in each well.
  • the system either automatically pre-focuses the region of the plate to be scanned using an autofocus procedure to "find focus" of the plate 102 or the user interactively pre-focuses 103 the scanning region by selecting three "tag" points which define the rectangular area to be scanned.
  • a least-squares fit "focal plane model” is then calculated from these tag points to estimate the focus of each well during an automated scan.
  • the focus of each well is estimated by interpolating from the focal plane model during a scan.
  • the software dynamically displays the scan status, including the number of cells analyzed, the current well being analyzed, images of each independent wavelength as they are acquired, and the result of the screen for each well as it is determined.
  • the plate 4 ( Figure 1) is scanned in a serpentine style as the software automatically moves the motorized microscope XY stage 3 from well to well and field to field within each well of a 96-well plate.
  • Those skilled in the programming art will recognize how to adapt software for scanning of other microplate formats such as 24, 48, and 384 well plates.
  • the scan pattern of the entire plate as well as the scan pattern of fields within each well are programmed.
  • the system adjusts sample focus with an autofocus procedure 104 ( Figure 9) through the Z axis focus drive 5, controls filter selection via a motorized filter wheel 19, and acquires and analyzes images of up to four different colors ("channels" or "wavelengths").
  • the autofocus procedure is called at a user selected frequency, typically for the first field in each well and then once every 4 to 5 fields within each well.
  • the autofocus procedure calculates the starting Z-axis point by interpolating from the pre-calculated plane focal model. Starting a programmable distance above or below this set point, the procedure moves the mechanical Z-axis through a number of different positions, acquires an image at each position, and finds the maximum of a calculated focus score that estimates the contrast of each image.
  • the Z position of the image with the maximum focus score determines the best focus for a particular field.
  • Those skilled in the art will recognize this as a variant of automatic focusing methods as described in Harms et al. in Cytometry 5 (1984), 236-243, Groen et al. in Cytometry 6 (1985), 81-91, and Firestone et al. in Cytometry 12 (1991), 195-206.
  • the camera's exposure time is separately adjusted for each dye to ensure a high-quality image from each channel.
  • Software procedures can be called, at the user's option, to correct for registration shifts between wavelengths by accounting for linear (X and Y) shifts between wavelengths before making any further measurements.
  • the electronic shutter 18 is controlled so that sample photo-bleaching is kept to a minimum. Background shading and uneven illumination can be corrected by the software using methods known in the art (Bright et al. (1987), J. Cell Biol. 104:1019-1033).
  • images are acquired of a primary marker 105 ( Figure 9) (typically cell nuclei counterstained with DAPI or PI fluorescent dyes) which are segmented ("identified") using an adaptive thresholding procedure.
  • the adaptive thresholding procedure 106 is used to dynamically select the threshold of an image for separating cells from the background.
  • the staining of cells with fluorescent dyes can vary to an unknown degree across cells in a microtiter plate sample as well as within images of a field of cells within each well of a microtiter plate. This variation can occur as a result of sample preparation and/or the dynamic nature of cells.
  • a global threshold is calculated for the complete image to separate the cells from background and account for field to field variation.
  • An alternative adaptive thresholding method utilizes local region thresholding in contrast to global image thresholding. Image analysis of local regions leads to better overall segmentation since staining of cell nuclei (as well as other labeled components) can vary across an image. Using this global/local procedure, a reduced resolution image (reduced in size by a factor of 2 to 4) is first globally segmented (using adaptive thresholding) to find regions of interest in the image. These regions then serve as guides to more fully analyze the same regions at full resolution. A more localized threshold is then calculated (again using adaptive thresholding) for each region of interest.
  • the output of the segmentation procedure is a binary image wherein the objects are white and the background is black.
  • This binary image also called a mask in the art, is used to determine if the field contains objects 107.
  • the mask is labeled with a blob labeling method whereby each object (or blob) has a unique number assigned to it.
  • Mo ⁇ hological features, such as area and shape, of the blobs are used to differentiate blobs likely to be cells from those that are considered artifacts.
  • the user pre-sets the mo ⁇ hological selection criteria by either typing in known cell mo ⁇ hological features or by using the interactive training utility. If objects of interest are found in the field, images are acquired for all other active channels 108.
  • the software determines if the object meets the criteria for a valid cell nucleus 111 by measuring its mo ⁇ hological features (size and shape). For each valid cell, the XYZ stage location is recorded, a small image of the cell is stored, and features are measured 112.
  • the cell scanning method of the present invention can be used to perform many different assays on cellular samples by applying a number of analytical methods simultaneously to measure features at multiple wavelengths.
  • An example of one such assay provides for the following measurements: 1. The total fluorescent intensity within the cell nucleus for colors 1-4
  • the shape of the cell nucleus for color 1 is described by three shape features: a) perimeter squared area b) box area ratio c) height width ratio
  • the average fluorescent intensity within the cell nucleus for colors 1-4 i.e. #1 divided by #2
  • the total fluorescent intensity of a ring outside the nucleus (see Figure 10) that represents fluorescence of the cell's cytoplasm (cytoplasmic mask) for colors 2-4
  • Features 1 through 4 are general features of the different cell screening assays of the invention. These steps are commonly used in a variety of image analysis applications and are well known in art (Russ (1992) The Image Processing Handbook, CRC Press Inc.; Gonzales et al. (1987), Digital Image Processing. Addison- Wesley Publishing Co. pp. 391-448).
  • Features 5-9 have been developed specifically to provide measurements of a cell's fluorescent molecules within the local cytoplasmic region of the cell and the translocation (i.e. movement) of fluorescent molecules from the cytoplasm to the nucleus. These features (steps 5-9) are used for analyzing cells in microplates for the inhibition of nuclear translocation.
  • a specific method measures the amount of probe in the nuclear region (feature 4) versus the local cytoplasmic region (feature 7) of each cell. Quantification of the difference between these two sub-cellular compartments provides a measure of cytoplasm-nuclear translocation (feature 9).
  • Feature 10 describes a screen used for counting of DNA or RNA probes within the nuclear region in colors 2-4.
  • probes are commercially available for identifying chromosome-specific DNA sequences (Life Technologies, Gaithersburg, MD; Genosys, Woodlands, TX; Biotechnologies, Inc., Richmond, CA; Bio 101, Inc., Vista, CA) Cells are three-dimensional in nature and when examined at a high magnification under a microscope one probe may be in-focus while another may be completely out-of-focus.
  • the cell screening method of the present invention provides for detecting three-dimensional probes in nuclei by acquiring images from multiple focal planes.
  • the software moves the Z-axis motor drive 5 ( Figure 1) in small steps where the step distance is user selected to account for a wide range of different nuclear diameters.
  • an image is acquired.
  • the maximum gray-level intensity from each pixel in each image is found and stored in a resulting maximum projection image.
  • the maximum projection image is then used to count the probes.
  • the above method works well in counting probes that are not stacked directly above or below another one.
  • users can select an option to analyze probes in each of the focal planes acquired. In this mode, the scanning system performs the maximum plane projection method as discussed above, detects probe regions of interest in this image, then further analyzes these regions in all the focal plane images.
  • the system After measuring cell features 112 ( Figure 9), the system checks if there are any unprocessed objects in the current field 113. If there are any unprocessed objects, it locates the next object 110 and determines whether it meets the criteria for a valid cell nucleus 111, and measures its features. Once all the objects in the current field are processed, the system determines whether analysis of the current plate is complete 114; if not, it determines the need to find more cells in the current well 115. If the need exists, the system advances the XYZ stage to the next field within the current well 109 or advances the stage to the next well 116 of the plate.
  • images and data can be reviewed with the system's image review, data review, and summary review facilities. All images, data, and settings from a scan are archived in the system's database for later review or for interfacing with a network information management system. Data can also be exported to other third-party statistical packages to tabulate results and generate other reports. Users can review the images alone of every cell analyzed by the system with an interactive image review procedure 117. The user can review data on a cell-by-cell basis using a combination of interactive graphs, a data spreadsheet of measured features, and images of all the fluorescence channels of a cell of interest with the interactive cell-by-cell data review procedure 118.
  • Graphical plotting capabilities are provided in which data can be analyzed via interactive graphs such as histograms and scatter plots. Users can review summary data that are accumulated and summarized for all cells within each well of a plate with an interactive well-by- well data review procedure 119. Hard copies of graphs and images can be printed on a wide range of standard printers.
  • reports can be generated on one or more statistics of the measured features.
  • Users can generate a graphical report of data summarized on a well-by-well basis for the scanned region of the plate using an interactive report generation procedure 120.
  • This report includes a summary of the statistics by well in tabular and graphical format and identification information on the sample.
  • the report window allows the operator to enter comments about the scan for later retrieval.
  • Multiple reports can be generated on many statistics and be printed with the touch of one button. Reports can be previewed for placement and data before being printed.
  • the above-recited embodiment of the method operates in a single high resolution mode referred to as the high content screening (HCS) mode.
  • HCS high content screening
  • the HCS mode provides sufficient spatial resolution within a well (on the order of 1 ⁇ m) to define the distribution of material within the well, as well as within individual cells in the well.
  • the high degree of information content accessible in that mode comes at the expense of speed and complexity of the required signal processing.
  • a high throughput system is directly coupled with the HCS either on the same platform or on two separate platforms connected electronically (e.g. via a local area network).
  • This embodiment of the invention referred to as a dual mode optical system, has the advantage of increasing the throughput of an HCS by coupling it with an HTS and thereby requiring slower high resolution data acquisition and analysis only on the small subset of wells that show a response in the coupled HTS.
  • High throughput 'whole plate' reader systems are well known in the art and are commonly used as a component of an HTS system used to screen large numbers of compounds (Beggs et al. (1997), supra; McCaffrey et al. (1996), supra ).
  • the HTS of the present invention is carried out on the microtiter plate or microwell array by reading many or all wells in the plate simultaneously with sufficient resolution to make determinations on a well-by-well basis. That is, calculations are made by averaging the total signal output of many or all the cells or the bulk of the material in each well. Wells that exhibit some defined response in the HTS (the 'hits') are flagged by the system. Then on the same microtiter plate or microwell array, each well identified as a hit is measured via HCS as described above.
  • the dual mode process involves:
  • the operator enters information 302 that describes the plate and its contents, specifies the filter settings and fluorescent channels to match the biological labels being used, the information sought and the camera settings to match the sample brightness. These parameters are stored in the system's database for easy retrieval for each automated run.
  • the microtiter plate or microwell array is loaded into the cell screening system 303 either manually or automatically by controlling a robotic loading device.
  • An optional environmental chamber 304 is controlled by the system to maintain the temperature, humidity and CO levels in the air surrounding live cells in the microtiter plate or microwell array.
  • An optional fluid delivery device 305 (see Figure 8) is controlled by the system to dispense fluids into the wells during the scan.
  • High throughput processing 306 is first performed on the microtiter plate or microwell array by acquiring and analyzing the signal from each of the wells in the plate.
  • the processing performed in high throughput mode 307 is illustrated in Figure 12 and described below.
  • Wells that exhibit some selected intensity response in this high throughput mode (“hits") are identified by the system.
  • the system performs a conditional operation 308 that tests for hits. If hits are found, those specific hit wells are further analyzed in high content (micro level) mode 309.
  • the processing performed in high content mode 312 is illustrated in Figure 13.
  • the system updates 310 the informatics database 311 with results of the measurements on the plate. If there are more plates to be analyzed 313 the system loads the next plate 303: otherwise the analysis of the plates terminates 314.
  • the following discussion describes the high throughput mode illustrated in
  • FIG. 12 The preferred embodiment of the system, the single platform dual mode screening system, will be described. Those skilled in the art will recognize that operationally the dual platform system simply involves moving the plate between two optical systems rather than moving the optics.
  • the system begins the HTS acquisition and analysis 401.
  • the HTS optical module is selected by controlling a motorized optical positioning device 402 on the dual mode system.
  • data from a primary marker on the plate is acquired 403 and wells are isolated from the plate background using a masking procedure 404. Images are also acquired in other fluorescence channels being used 405. The region in each image corresponding to each well 406 is measured 407.
  • a feature calculated from the measurements for a particular well is compared with a predefined threshold or intensity response 408, and based on the result the well is either flagged as a "hit" 409 or not.
  • the locations of the wells flagged as hits are recorded for subsequent high content mode processing. If there are wells remaining to be processed 410 the program loops back 406 until all the wells have been processed 411 and the system exits high throughput mode.
  • the system starts the high content mode processing 501 defined in Figure 13.
  • the system selects the HCS optical module 502 by controlling the motorized positioning system.
  • the XY stage location of the well is retrieved from memory or disk and the stage is then moved to the selected stage location 503.
  • the autofocus procedure 504 is called for the first field in each hit well and then once every 5 to 8 fields within each well.
  • images are acquired of the primary marker 505 (typically cell nuclei counterstained with DAPI, Hoechst or PI fluorescent dye). The images are then segmented (separated into regions of nuclei and non-nuclei) using an adaptive thresholding procedure 506.
  • the primary marker 505 typically cell nuclei counterstained with DAPI, Hoechst or PI fluorescent dye
  • the output of the segmentation procedure is a binary mask wherein the objects are white and the background is black.
  • This binary image also called a mask in the art, is used to determine if the field contains objects 507.
  • the mask is labeled with a blob labeling method whereby each object (or blob) has a unique number assigned to it. If objects are found in the field, images are acquired for all other active channels 508, otherwise the stage is advanced to the next field 514 in the current well. Each object is located in the image for further analysis 509. Mo ⁇ hological features, such as area and shape of the objects, are used to select objects likely to be cell nuclei 510. and discard (do no further processing on) those that are considered artifacts.
  • the XYZ stage location is recorded, a small image of the cell is stored, and assay specific features are measured 511.
  • the system then performs multiple tests on the cells by applying several analytical methods to measure features at each of several wavelengths. After measuring the cell features, the systems checks if there are any unprocessed objects in the current field 512. If there are any unprocessed objects, it locates the next object 509 and determines whether it meets the criteria for a valid cell nucleus 510. and measures its features. After processing all the objects in the current field, the system deteremines whether it needs to find more cells or fields in the current well 513.
  • a method of kinetic live cell screening is provided.
  • the previously described embodiments of the invention are used to characterize the spatial distribution of cellular components at a specific point in time, the time of chemical fixation. As such, these embodiments have limited utility for implementing kinetic based screens, due to the sequential nature of the image acquisition, and the amount of time required to read all the wells on a plate.
  • the kinetic live cell extension of the invention enables the design and use of screens in which a biological process is characterized by its kinetics instead of, or in addition to, its spatial characteristics.
  • a response in live cells can be measured by adding a reagent to a specific well and making multiple measurements on that well with the appropriate timing.
  • This dynamic live cell embodiment of the invention therefore includes apparatus for fluid delivery to individual wells of the system in order to deliver reagents to each well at a specific time in advance of reading the well. This embodiment thereby allows kinetic measurements to be made with temporal resolution of seconds to minutes on each well of the plate.
  • the acquisition control program is modified to allow repetitive data collection from sub-regions of the plate, allowing the system to read other wells between the time points required for an individual well.
  • Figure 8 describes an example of a fluid delivery device for use with the live cell embodiment of the invention and is described above.
  • This set-up allows one set of pipette tips 705, or even a single pipette tip, to deliver reagent to all the wells on the plate.
  • the bank of syringe pumps 701 can be used to deliver fluid to 12 wells simultaneously, or to fewer wells by removing some of the tips 705.
  • the temporal resolution of the system can therefore be adjusted, without sacrificing data collection efficiency, by changing the number of tips and the scan pattern as follows.
  • the data collection and analysis from a single well takes about 5 seconds. Moving from well to well and focusing in a well requires about 5 seconds, so the overall cycle time for a well is about 10 seconds.
  • the overall time to collect a kinetic data set from the plate is then simply the time to perform a single scan of the plate, multiplied by the number of time points required. Typically, 1 time point before addition of compounds and 2 or 3 time points following addition should be sufficient for screening pu ⁇ oses.
  • Figure 14 shows the acquisition sequence used for kinetic analysis.
  • the start of processing 801 is configuration of the system, much of which is identical to the standard HCS configuration.
  • the operator must enter information specific to the kinetic analysis being performed 802, such as the sub-region size, the number of time points required, and the required time increment.
  • a sub-region is a group of wells that will be scanned repetitively in order to accumulate kinetic data.
  • the size of the sub-region is adjusted so that the system can scan a whole sub-region once during a single time increment, thus minimizing wait times.
  • the optimum sub-region size is calculated from the setup parameters, and adjusted if necessary by the operator.
  • the acquisition sequence performed in each well is exactly the same as that required for the specific HCS being run in kinetic mode.
  • Figure 15 details a flow chart for that processing. All of the steps between the start 901 and the return 902 are identical to those described as steps 504 - 514 in Figure 13.
  • the system After processing each well in a sub-region, the system checks to see if all the wells in the sub-region have been processed 806 ( Figure 14), and cycles through all the wells until the whole region has been processed. The system then moves the plate into position for fluid addition, and controls fluidic system delivery of fluids to the entire sub-region 807. This may require multiple additions for sub-regions which span several rows on the plate, with the system moving the plate on the X,Y stage between additions. Once the fluids have been added, the system moves to the first well in the sub-region 808 to begin acquisition of time points. The data is acquired from each well 809 and as before the system cycles through all the wells in the sub-region 810.
  • the system After each pass through the sub-region, the system checks whether all the time points have been collected 811 and if not, pauses 813 if necessary 812 to stay synchronized with the requested time increment. Otherwise, the system checks for additional sub-regions on the plate 814 and either moves to the next sub-region 803 or finishes 815.
  • the kinetic analysis mode comprises operator identification of sub-regions of the microtiter plate or microwells to be screened, based on the kinetic response to be investigated, with data acquisitions within a sub-region prior to data acquisition in subsequent sub- regions.
  • cell screening methods and machine readable storage medium comprising a program containing a set of instructions for causing a cell screening system to execute procedures for defining the distribution and activity of specific cellular constituents and processes.
  • the cell screening system comprises a high magnification fluorescence optical system with a stage adapted for holding cells and a means for moving the stage, a digital camera, a light source for receiving and processing the digital data from the digital camera, and a computer means for receiving and processing the digital data from the digital camera.
  • This aspect of the invention comprises programs that instruct the cell screening system to define the distribution and activity of specific cellular constituents and processes, using the luminescent probes, the optical imaging system, and the pattern recognition software of the invention.
  • Preferred embodiments of the machine readable storage medium comprise programs consisting of a set of instructions for causing a cell screening system to execute the procedures set forth in Figures 9, 11, 12, 13, 14 or 15.
  • Another preferred embodiment comprises a program consisting of a set of instructions for causing a cell screening system to execute procedures for detecting the distribution and activity of specific cellular constituents and processes.
  • the cellular processes include, but are not limited to, nuclear translocation of a protein, cellular mo ⁇ hology, apoptosis, receptor intemalization, and protease-induced translocation of a protein.
  • the cell screening methods are used to identify compounds that modify the various cellular processes.
  • the cells can be contacted with a test compound, and the effect of the test compound on a particular cellular process can be analyzed.
  • the cells can be contacted with a test compound and a known agent that modifies the particular cellular process, to determine whether the test compound can inhibit or enhance the effect of the known agent.
  • the methods can be used to identify test compounds that increase or decrease a particular cellular response, as well as to identify test compounds that affects the ability of other agents to increase or decrease a particular cellular response.
  • the locations containing cells are analyzed using the above methods at low resolution in a high throughput mode, and only a subset of the locations containing cells are analyzed in a high content mode to obtain luminescent signals from the luminescently labeled reporter molecules in subcellular compartments of the cells being analyzed.
  • the following examples are intended for pu ⁇ oses of illustration only and should not be construed to limit the scope of the invention, as defined in the claims appended hereto.
  • Regulation of transcription of some genes involves activation of a transcription factor in the cytoplasm, resulting in that factor being transported into the nucleus where it can initiate transcription of a particular gene or genes.
  • This change in transcription factor distribution is the basis of a screen for the cell-based screening system to detect compounds that inhibit or induce transcription of a particular gene or group of genes. A general description of the screen is given followed by a specific example.
  • the distribution of the transcription factor is determined by labeling the nuclei with a DNA specific fluorophore like Hoechst 33423 and the transcription factor with a specific fluorescent antibody. After autofocusing on the Hoechst labeled nuclei, an image of the nuclei is acquired in the cell-based screening system and used to create a mask by one of several optional thresholding methods, as described supra. The mo ⁇ hological descriptors of the regions defined by the mask are compared with the user defined parameters and valid nuclear masks are identified and used with the following method to extract transcription factor distributions. Each valid nuclear mask is eroded to define a slightly smaller nuclear region.
  • Figure 10A illustrates an unstimulated cell with its nucleus 200 labeled with a blue fluorophore and a transcription factor in the cytoplasm 201 labeled with a green fluorophore.
  • Figure 10B illustrates the nuclear mask 202 derived by the cell-based screening system.
  • Figure 10C illustrates the cytoplasm 203 of the unstimulated cell imaged at a green wavelength.
  • Figure 10D illustrates the nuclear mask 202 is eroded (reduced) once to define a nuclear sampling region 204 with minimal cytoplasmic distribution.
  • the nucleus boundary 202 is dilated (expanded) several times to form a ring that is 2-3 pixels wide that is used to define the cytoplasmic sampling region 205 for the same cell.
  • Figure 10E further illustrates a side view which shows the nuclear sampling region 204 and the cytoplasmic sampling region 205. Using these two sampling regions, data on nuclear translocation can be automatically analyzed by the cell-based screening system on a cell by cell basis.
  • Figure 10F-J illustrates the strategy for determining nuclear translocation in a stimulated cell.
  • Figure 10F illustrates a stimulated cell with its nucleus 206 labeled with a blue fluorophore and a transcription factor in the cytoplasm 207 labeled with a green fluorophore.
  • the nuclear mask 208 in Figure 10G is derived by the cell based screening system.
  • Figure 10H illustrates the cytoplasm 209 of a stimulated cell imaged at a green wavelength.
  • Figure 101 illustrates the nuclear sampling region 211 and cytoplasmic sampling region 212 of the stimulated cell.
  • Figure 10J further illustrates a side view which shows the nuclear sampling region 21 1 and the cytoplasmic sampling region 212.
  • a specific application of this method has been used to validate this method as a screen.
  • a human cell line was plated in 96 well microtiter plates. Some rows of wells were titrated with IL-1, a known inducer of the NF-KB transcription factor. The cells were then fixed and stained by standard methods with a fluorescein labeled antibody to the transcription factor, and Hoechst 33423. The cell-based screening system was used to acquire and analyze images from this plate and the NucCyt Difference was found to be strongly correlated with the amount of agonist added to the wells as illustrated in Figure 16.
  • NucCyt ratio gives consistent results over a wide range of cell densities and reagent concentrations, and can therefore be routinely used to screen compound libraries for specific nuclear translocation activity. Furthermore, the same method can be used with antibodies to other transcription factors, or GFP-transcription factor chimeras, or fluorescently labeled transcription factors introduced into living or fixed cells, to screen for effects on the regulation of transcription factor activity.
  • Figure 18 is a representative display on a PC screen of data which was obtained in accordance with Example 1.
  • Graph 1 180 plots the difference between the average antibody fluorescence in the nuclear sampling region and cytoplasmic sampling region, NucCyt Difference verses Well #.
  • Graph 2 181 plots the average fluorescence of the antibody in the nuclear sampling region, NPl average, versus the Well #.
  • Graph 3 182 plots the average antibody fluorescence in the cytoplasmic sampling region, LIP1 average, versus Well #.
  • the software permits displaying data from each cell.
  • Figure 18 shows a screen display 183. the nuclear image 184. and the fluorescent antibody image 185 for cell #26.
  • NucCyt Difference referced to in graph 1 180 of Figure 18 is the difference between the average cytoplasmic probe (fluorescent reporter molecule) intensity and the average nuclear probe (fluorescent reporter molecule) intensity.
  • NPl average referred to in graph 2 181 of Figure 18 is the average of cytoplasmic probe (fluorescent reporter molecule) intensity within the nuclear sampling region.
  • L1P1 average referred to in graph 3 182 of Figure 18 is the average probe (fluorescent reporter molecule) intensity within the cytoplasmic sampling region.
  • this aspect of the invention can be performed using other transcription factors that translocate from the cytoplasm to the nucleus upon activation.
  • activation of the c-fos transcription factor was assessed by defining its spatial position within cells. Activated c-fos is found only within the nucleus, while inactivated c-fos resides within the cytoplasm.
  • 3T3 cells were plated at 5000-10000 cells per well in a Polyfiltronics 96- well plate. The cells were allowed to attach and grow overnight.
  • the cells were rinsed twice with 100 ⁇ l serum-free medium, incubated for 24-30 hours in serum-free MEM culture medium, and then stimulated with platelet derived growth factor (PDGF-BB) (Sigma Chemical Co., St. Louis, MO) diluted directly into serum free medium at concentrations ranging from 1-50 ng/ml for an average time of 20 minutes.
  • PDGF-BB platelet derived growth factor
  • HBSS IX Hanks buffered saline solution
  • transcription factors include, but are not limited to fos and jun homologs, NF-KB (nuclear factor kappa from B cells), NFAT (nuclear factor of activated T-lymphocytes), and STATs (signal transducer and activator of transcription) factors (For example, see Strehlow, I., and Schindler, C. 1998. J. Biol. Chem. 273:28049-28056; Chow, et al. 1997 Science.
  • indicator cells are treated with test compounds and the distribution of luminescently labeled transcription factor is measured in space and time using a cell screening system, such as the one disclosed above.
  • the luminescently labeled transcription factor may be expressed by or added to the cells either before, together with, or after contacting the cells with a test compound.
  • the transcription factor may be expressed as a luminescently labeled protein chimera by transfected indicator cells.
  • the luminescently labeled transcription factor may be expressed, isolated, and bulk-loaded into the indicator cells as described above, or the transcription factor may be luminescently labeled after isolation.
  • the transcription factor is expressed by the indicator cell, which is subsequently contacted with a luminescent label, such as an antibody, that detects the transcription factor.
  • kits for analyzing transcription factor activation, comprising an antibody that specifically recognizes a transcription factor of interest, and instructions for using the antibody for carrying out the methods described above.
  • the transcription factor-specific antibody, or a secondary antibody that detects the transcription factor antibody is luminescently labeled.
  • the kit contains cells that express the transcription factor of interest, and/or the kit contains a compound that is known to modify activation of the transcription factor of interest, including but not limited to platelet derived growth factor (PDGF) and serum, which both modify fos activation; and interleukin 1 (IL- 1 ) and tumor necrosis factor (TNF), which both modify NF-KB activation.
  • PDGF platelet derived growth factor
  • IL- 1 interleukin 1
  • TNF-KB activation tumor necrosis factor
  • the kit comprises a recombinant expression vector comprising a nucleic acid encoding a transcription factor of interest that translocates from the cytoplasm to the nucleus upon activation, and instructions for using the expression vector to identify compounds that modify transcription factor activation in a cell of interest.
  • the kits contain a purified, luminescently labeled transcription factor.
  • the transcription factor is expressed as a fusion protein with a luminescent protein, including but not limited to green fluorescent protein, luceriferase, or mutants or fragments thereof.
  • the kit further contains cells that are transfected with the expression vector, an antibody or fragment that specifically bind to the transcription factor of interest, and/or a compound that is known to modify activation of the transcription factor of interest (as above).
  • the cytoplasm to nucleus screening methods can also be used to analyze the activation of any protein kinase that is present in an inactive state in the cytoplasm and is transported to the nucleus upon activation, or that phosphorylates a substrate that translocates from the cytoplasm to the nucleus upon phosphorylation.
  • protein kinases include, but are not limited to extracellular signal-regulated protein kinases (ERKs), c-Jun amino -terminal kinases (JNKs), Fos regulating protein kinases (FRKs), p38 mitogen activated protein kinase (p38MAPK), protein kinase A (PKA), and mitogen activated protein kinase kinases (MAPKKs).
  • ERKs extracellular signal-regulated protein kinases
  • JNKs c-Jun amino -terminal kinases
  • FRKs Fos regulating protein kinases
  • p38MAPK p38 mitogen activated protein kinase
  • PKA protein kinase A
  • MAPKKs mitogen activated protein kinase kinases
  • protein kinase activity is assayed by monitoring translocation of a luminescently labeled protein kinase substrate from the cytoplasm to the nucleus after being phosphorylated by the protein kinase of interest.
  • the substrate is non-phosphorylated and cytoplasmic prior to phosphorylation, and is translocated to the nucleus upon phosphorylation by the protein kinase.
  • the protein kinase itself translocates from the cytoplasm to the nucleus in this embodiment.
  • substrates and the corresponding protein kinase
  • indicator cells are treated with test compounds and the distribution of luminescently labeled protein kinase or protein kinase substrate is measured in space and time using a cell screening system, such as the one disclosed above.
  • the luminescently labeled protein kinase or protein kinase substrate may be expressed by or added to the cells either before, together with, or after contacting the cells with a test compound.
  • the protein kinase or protein kinase substrate may be expressed as a luminescently labeled protein chimera by transfected indicator cells.
  • the luminescently labeled protein kinase or protein kinase substrate may be expressed, isolated, and bulk-loaded into the indicator cells as described above, or the protein kinase or protein kinase substrate may be luminescently labeled after isolation.
  • the protein kinase or protein kinase substrate is expressed by the indicator cell, which is subsequently contacted with a luminescent label, such as a labeled antibody, that detects the protein kinase or protein kinase substrate.
  • protein kinase activity is assayed by monitoring the phosphorylation state (ie: phosphorylated or not phosphorylated) of a protein kinase substrate.
  • phosphorylation state ie: phosphorylated or not phosphorylated
  • phosphorylation state is monitored by contacting the cells with an antibody that binds only to the phosphorylated form of the protein kinase substrate of interest (For example, as disclosed in U.S. Patent No. 5,599,681).
  • a biosensor of phosphorylation is used.
  • a luminescently labeled protein or fragment thereof can be fused to a protein that has been engineered to contain (a) a phosphorylation site that is recognized by a protein kinase of interest; and (b) a nuclear localization signal that is unmasked by the phosphorylation.
  • a biosensor will thus be translocated to the nucleus upon phosphorylation, and its translocation can be used as a measure of protein kinase activation.
  • kits for analyzing protein kinase activation, comprising a primary antibody that specifically binds to a protein kinase, a protein kinase substrate, or a phosphorylated form of the protein kinase substrate of interest and instructions for using the primary antibody to identify compounds that modify protein kinase activation in a cell of interest.
  • the primary antibody, or a secondary antibody that detects the primary antibody is luminescently labeled.
  • the kit further comprises cells that express the protein kinase of interest, and/or a compound that is known to modify activation of the protein kinase of interest, including but not limited to dibutyryl cAMP (modifies PKA), forskolin (PKA), and anisomycin (p38MAPK).
  • a compound that is known to modify activation of the protein kinase of interest including but not limited to dibutyryl cAMP (modifies PKA), forskolin (PKA), and anisomycin (p38MAPK).
  • kits comprise an expression vector encoding a protein kinase or a protein kinase substrate of interest that translocates from the cytoplasm to the nucleus upon activation and instructions for using the expression vector to identify compounds that modify protein kinase activation in a cell of interest.
  • the kits contain a purified, luminescently labeled protein kinase or protein kinase substrate.
  • the protein kinase or protein kinase substrate of interest is expressed as a fusion protein with a luminescent protein.
  • the kit further comprises cells that are transfected with the expression vector, an antibody or fragment thereof that specifically binds to the protein kinase or protein kinase substrate of interest, and/or a compound that is known to modify activation of the protein kinase of interest, (as above)
  • the present invention comprises a machine readable storage medium comprising a program containing a set of instructions for causing a cell screening system to execute the methods disclosed for analyzing transcription factor or protein kinase activation, wherein the cell screening system comprises an optical system with a stage adapted for holding a plate containing cells, a digital camera, a means for directing fluorescence or luminescence emitted from the cells to the digital camera, and a computer means for receiving and processing the digital data from the digital camera.
  • Changes in cell size are associated with a number of cellular conditions, such as hypertrophy, cell attachment and spreading, differentiation, growth and division, necrotic and programmed cell death, cell motility, mo ⁇ hogenesis, tube formation, and colony formation.
  • cellular hypertrophy has been associated with a cascade of alterations in gene expression and can be characterized in cell culture by an alteration in cell size, that is clearly visible in adherent cells growing on a coverslip.
  • Cell size can also be measured to determine the attachment and spreading of adherent cells.
  • Cell spreading is the result of selective binding of cell surface receptors to substrate ligands and subsequent activation of signaling pathways to the cytoskeleton.
  • Cell attachment and spreading to substrate molecules is an important step for the metastasis of cancer cells, leukocyte activation during the inflammatory response, keratinocyte movement during wound healing, and endothelial cell movement during angiogenesis.
  • Compounds that affect these surface receptors, signaling pathways, or the cytoskeleton will affect cell spreading and can be screened by measuring cell size.
  • Total cellular area can be monitored by labeling the entire cell body or the cell cytoplasm using cytoskeletal markers, cytosolic volume markers, or cell surface markers, in conjunction with a DNA label. Examples of such labels (many available from Molecular Probes (Eugene, Oregon) and Sigma Chemical Co. (St. Louis, Missouri)) include the following:
  • CMFDA Chloromethylfluorescein diacetate
  • D1ICI6 Dihexadecyl tetramethylindocarbocyamne perchlorate
  • Lectins to oligosacca ⁇ des such as fluorescem concanavalm A or wheat germ agglutinm
  • Antibodies to various surface proteins such as epidermal growth factor
  • Cells are stained live or after fixation and the cell area can be measured.
  • live cells stained with DiIC16 have homogeneously labeled plasma membranes, and the projected cross-sectional area of the cell is uniformly discriminated from background by fluorescence intensity of the dye.
  • Live cells stained with cytosolic stains such as CMFDA produce a fluorescence intensity that is proportional to cell thickness.
  • cell labeling is dimmer in thin regions of the cell, total cell area can be discriminated from background.
  • Fixed cells can be stained with cytoskeletal markers such as ALEXATM 488 phalloidm that label polymerized actin. Phalloidm does not homogeneously stain the cytoplasm, but still permits discrimination of the total cell area from background.
  • Cellular hypertrophy A screen to analyze cellular hypertrophy is implemented using the following strategy.
  • Primary rat myocytes can be cultured in 96 well plates, treated with various compounds and then fixed and labeled with a fluorescent marker for the cell membrane or cytoplasm, or cytoskeleton, such as an antibody to a cell surface marker or a fluorescent marker for the cytoskeleton like rhodamine-phalloidin, in combination with a DNA label like Hoechst.
  • cytoplasmic image After focusing on the Hoechst labeled nuclei, two images are acquired, one of the Hoechst labeled nuclei and one of the fluorescent cytoplasm image.
  • the nuclei are identified by thresholding to create a mask and then comparing the mo ⁇ hological descriptors of the mask with a set of user defined descriptor values.
  • Each non-nucleus image (or "cytoplasmic image") is then processed separately.
  • the original cytoplasm image can be thresholded, creating a cytoplasmic mask image. Local regions containing cells are defined around the nuclei. The limits of the cells in those regions are then defined by a local dynamic threshold operation on the same region in the fluorescent antibody image.
  • a sequence of erosions and dilations is used to separate slightly touching cells and a second set of mo ⁇ hological descriptors is used to identify single cells.
  • the area of the individual cells is tabulated in order to define the distribution of cell sizes for comparison with size data from normal and hypertrophic cells.
  • the aggregate whole nucleus area is the number of nonzero pixels in the nuclear mask.
  • the average whole nucleus area is the aggregate whole nucleus area divided by the total number of nuclei.
  • the aggregate cytoplasm intensity is the sum of the intensities of all pixels in the cytoplasmic mask.
  • the cytoplasmic area per nucleus is the total cytoplasmic area divided by the total nucleus count.
  • the cytoplasmic intensity per nucleus is the aggregate cytoplasm intensity divided by the total nucleus count.
  • the average cytoplasm intensity is the aggregate cytoplasm intensity divided by the cytoplasm area.
  • the cytoplasm nucleus ratio is the total cytoplasm area divided by the total nucleus area.
  • one or more fluorescent antibodies to other cellular proteins can be included. Images of these additional labeled proteins can be acquired and stored with the above images, for later review, to identify anomalies in the distribution and mo ⁇ hology of these proteins in hypertrophic cells.
  • This example of a multi-parametric screen allows for simultaneous analysis of cellular hypertrophy and changes in actin or myosin distribution.
  • the methods can be applied to analyzing hypertrophy, or general mo ⁇ hological changes in any cell type.
  • Cell morphology assays for prostate carcinoma Cell spreading is a measure of the response of cell surface receptors to substrate attachment ligands. Spreading is proportional to the ligand concentration or to the concentration of compounds that reduce receptor-ligand function.
  • selective cell-substrate attachment is prostate carcinoma cell adhesion to the extracellular matrix protein collagen. Prostate carcinoma cells metastasize to bone via selective adhesion to collagen.
  • PC3 human prostate carcinoma cells were cultured in media with appropriate stimulants and are passaged to collagen coated 96 well plates.
  • Ligand concentration can be varied or inhibitors of cell spreading can be added to the wells.
  • Examples of compounds that can affect spreading are receptor antagonists such as integrin- or proteoglycan-blocking antibodies, signaling inhibitors including phosphatidyl inositol-3 kinase inhibitors, and cytoskeletal inhibitors such as cytochalasin D.
  • receptor antagonists such as integrin- or proteoglycan-blocking antibodies
  • signaling inhibitors including phosphatidyl inositol-3 kinase inhibitors
  • cytoskeletal inhibitors such as cytochalasin D.
  • the size of cells under these various conditions can be distinguished above background levels.
  • the number of cells per field is determined by measuring the number of nuclei stained with the Hoechst DNA dye.
  • the area per cell is found by dividing the cytoplasmic area (phalloidin image) by the cell number (Hoechst image).
  • the size of cells is proportional to the ligand-receptor function. Since the area is determined by ligand concentration and by the resultant function of the cell, drug efficacy, as well as drug potency, can be determined by this cell-based assay. Other measurements can be made as discussed above for cellular hypertrophy.
  • the methods for analyzing cellular mo ⁇ hology can be used in a combined high throughput-high content screen.
  • the high throughput mode scans the whole well for an increase in fluorescent phalloidin intensity.
  • a threshold is set above which both nuclei (Hoechst) and cells (phalloidin) are measured in a high content mode.
  • an environmental biosensor (examples include, but are not limited to, those biosensors that are sensitive to calcium and pH changes) is added to the cells, and the cells are contacted with a compound. The cells are scanned in a high throughput mode, and those wells that exceed a pre-determined threshold for luminescence of the biosensor are scanned in a high content mode.
  • kits for analyzing cellular mo ⁇ hology, comprising a luminescent compound that can be used to specifically label the cell cytoplasm, membrane, or cytoskeleton (such as those described above), and instructions for using the luminescent compound to identify test stimuli that induce or inhibit changes in cellular mo ⁇ hology according to the above methods.
  • the kit further comprises a luminescent marker for cell nuclei.
  • the kit comprises at least one compound that is known to modify cellular mo ⁇ hology, including, but not limited to integrin- or proteoglycan- blocking antibodies, signaling inhibitors including phosphatidyl inositol-3 kinase inhibitors, and cytoskeletal inhibitors such as cytochalasin D.
  • the present invention comprises a machine readable storage medium comprising a program containing a set of instructions for causing a cell screening system to execute the disclosed methods for analyzing cellular mo ⁇ hology
  • the cell screening system comprises an optical system with a stage adapted for holding a plate containing cells, a digital camera, a means for directing fluorescence or luminescence emitted from the cells to the digital camera, and a computer means for receiving and processing the digital data from the digital camera.
  • Example 3 Dual Mode High Throughput and High-Content Screen
  • the following example is a screen for activation of a G-protein coupled receptor
  • GPCR as detected by the translocation of the GPCR from the plasma membrane to a proximal nuclear location.
  • This example illustrates how a high throughput screen can be coupled with a high-content screen in the dual mode System for Cell Based
  • G-protein coupled receptors are a large class of 7 trans-membrane domain cell surface receptors. Ligands for these receptors stimulate a cascade of secondary signals in the cell, which may include, but are not limited to, Ca ++ transients, cyclic AMP production, inositol triphosphate (IP 3 ) production and phosphorylation. Each of these signals are rapid, occuring in a matter of seconds to minutes, but are also generic. For example, many different GPCRs produce a secondary Ca ++ signal when activated. Stimulation of a GPCR also results in the transport of that GPCR from the cell surface membrane to an internal, proximal nuclear compartment. This intemalization is a much more receptor-specific indicator of activation of a particular receptor than are the secondary signals described above.
  • Figure 19 illustrates a dual mode screen for activation of a GPCR.
  • Cells carrying a stable chimera of the GPCR with a blue fluorescent protein (BFP) would be loaded with the acetoxymethylester form of Fluo-3, a cell permeable calcium indicator (green fluorescence) that is trapped in living cells by the hydrolysis of the esters. They would then be deposited into the wells of a microtiter plate 601. The wells would then be treated with an array of test compounds using a fluid delivery system, and a short sequence of Fluo-3 images of the whole microtiter plate would be acquired and analyzed for wells exhibiting a calcium response (i.e., high throughput mode). The images would appear like the illustration of the microtiter plate 601 in Figure 19.
  • BFP blue fluorescent protein
  • a small number of wells such as wells C4 and E9 in the illustration, would fluoresce more brightly due to the Ca ++ released upon stimulation of the receptors.
  • the locations of wells containing compounds that induced a response 602, would then be transferred to the HCS program and the optics switched for detailed cell by cell analysis of the blue fluorescence for evidence of GPCR translocation to the perinuclear region.
  • the bottom of Figure 19 illustrates the two possible outcomes of the analysis of the high resolution cell data.
  • the camera images a sub-region 604 of the well area 603. producing images of the fluorescent cells 605.
  • the following is an example of a screen to measure the kinetics of intemalization of a receptor.
  • the stimulation of a GPCR results in the intemalization of the receptor, with a time course of about 15 min.
  • Simply detecting the endpoint as internalized or not, may not be sufficient for defining the potency of a compound as a GPCR agonist or antagonist.
  • 3 time points at 5 min intervals would provide information not only about potency during the time course of measurement, but would also allow extrapolation of the data to much longer time periods.
  • the sub-region would be defined as two rows, the sampling interval as 5 minutes and the total number of time points 3.
  • HCS human glucocorticoid receptor
  • hormone receptors are excellent drug targets because their activity lies at the apex of key intracellular signaling pathways. Therefore, a high-content screen of hGR translocation has distinct advantage over in vitro ligand-receptor binding assays.
  • the availability of up to two more channels of fluorescence in the cell screening system of the present invention permits the screen to contain two additional parameters in parallel, such as other receptors, other distinct targets or other cellular processes.
  • Plasmid construct A eukaryotic expression plasmid containing a coding sequence for a green fluorescent protein - human glucocorticoid receptor (GFP-hGR) chimera was prepared using GFP mutants (Palm et al., Nat. Struct. Biol. 4:361 (1997). The construct was used to transfect a human cervical carcinoma cell line (HeLa). Cell preparation and transfection.
  • GFP-hGR green fluorescent protein - human glucocorticoid receptor
  • HeLa cells (ATCC CCL-2) were trypsinized and plated using DMEM containing 5% charcoal/dextran-treated fetal bovine serum (FBS) (HyClone) and 1% penicillin-streptomycin (C-DMEM) 12-24 hours prior to transfection and incubated at 37°C and 5% CO . Transfections were performed by calcium phosphate co-precipitation (Graham and Van der Eb, Virology 52:456, 1973; Sambrook et al., (1989). Molecular Cloning: A Laboratory Manual, Second ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989) or with Lipofectamine (Life Technologies, Gaithersburg, MD).
  • FBS fetal bovine serum
  • C-DMEM penicillin-streptomycin
  • the medium was replaced, prior to transfection, with DMEM containing 5% charcoal/dextran-treated FBS.
  • Cells were incubated with the calcium phosphate-DNA precipitate for 4-5 hours at 37°C and 5% CO 2 , washed 3-4 times with DMEM to remove the precipitate, followed by the addition of C-DMEM.
  • Lipofectamine transfections were performed in serum-free DMEM without antibiotics according to the manufacturer's instructions (Life Technologies, Gaithersburg, MD). Following a 2-3 hour incubation with the DNA-liposome complexes, the medium was removed and replaced with C-DMEM. All transfected cells in 96-well microtiter plates were incubated at 33°C and 5% CO for 24-48 hours prior to drug treatment. Experiments were performed with the receptor expressed transiently in HeLa cells.
  • Dexamethasone induction of GFP-hGR translocation To obtain receptor- ligand translocation kinetic data, nuclei of transfected cells were first labeled with 5 ⁇ g/ml Hoechst 33342 (Molecular Probes) in C-DMEM for 20 minutes at 33°C and 5% CO 2 . Cells were washed once in Hank's Balanced Salt Solution (HBSS) followed by the addition of 100 nM dexamethasone in HBSS with 1% charcoal/dextran-treated FBS.
  • HBSS Hank's Balanced Salt Solution
  • transfected HeLa cells were first washed with DMEM and then incubated at 33°C and 5% CO 2 for 1 h in the presence of 0 - 1000 nM dexamethasone in DMEM containing 1% charcoal/dextran- treated FBS.
  • Cells were analyzed live or they were rinsed with HBSS, fixed for 15 min with 3.7% formaldehyde in HBSS, stained with Hoechst 33342, and washed before analysis.
  • the intracellular GFP-hGR fluorescence signal was not diminished by this fixation procedure. Image acquisition and analysis.
  • Kinetic data were collected by acquiring fluorescence image pairs (GFP-hGR and Hoechst 33342-labeled nuclei) from fields of living cells at 1 min intervals for 30 min after the addition of dexamethasone. Likewise, image pairs were obtained from each well of the fixed time point screening plates 1 h after the addition of dexamethasone. In both cases, the image pairs obtained at each time point were used to define nuclear and cytoplasmic regions in each cell. Translocation of GFP-hGR was calculated by dividing the integrated fluorescence intensity of GFP-hGR in the nucleus by the integrated fluorescence intensity of the chimera in the cytoplasm or as a nuclear-cytoplasmic difference of GFP fluorescence.
  • FIG. 20 schematically displays the drug-induced cytoplasm 253 to nucleus 252 translocation of the human glucocorticoid receptor.
  • the upper pair of schematic diagrams depicts the localization of GFP-hGR within the cell before 250 (A) and after 251 (B) stimulation with dexamethasone. Under these experimental conditions, the drug induces a large portion of the cytoplasmic GFP-hGR to translocate into the nucleus.
  • This redistribution is quantified by determining the integrated intensities ratio of the cytoplasmic and nuclear fluorescence in treated 255 and untreated 254 cells.
  • the lower pair of fluorescence micrographs show the dynamic redistribution of GFP-hGR in a single cell, before 254 and after 255 treatment.
  • the HCS is performed on wells containing hundreds to thousands of transfected cells and the translocation is quantified for each cell in the field exhibiting GFP fluorescence.
  • the use of a stably transfected cell line would yield the most consistently labeled cells, the heterogeneous levels of GFP-hGR expression induced by transient transfection did not interfere with analysis by the cell screening system of the present invention.
  • the cell screening system scans each well of the plate, images a population of cells in each, and analyzes cells individually.
  • two channels of fluorescence are used to define the cytoplasmic and nuclear distribution of the GFP-hGR within each cell.
  • Depicted in Figure 21 is the graphical user interface of the cell screening system near the end of a GFP-hGR screen.
  • the user interface depicts the parallel data collection and analysis capability of the system.
  • the windows labeled "Nucleus” 261 and "GFP-hGR" 262 show the pair of fluorescence images being obtained and analyzed in a single field.
  • the window labeled "Color Overlay" 260 is formed by pseudocoloring the above images and merging them so the user can immediately identify cellular changes.
  • the "Stored Object Regions" window 265. an image containing each analyzed cell and its neighbors is presented as it is archived. Furthermore, as the HCS data are being collected, they are analyzed, in this case for GFP-hGR translocation, and translated into an immediate "hit" response.
  • the 96 well plate depicted in the lower window of the screen 267 shows which wells have met a set of user-defined screening criteria. For example, a white-colored well 269 indicates that the drag-induced translocation has exceeded a predetermined threshold value of 50%. On the other hand, a black-colored well 270 indicates that the drug being tested induced less than 10% translocation. Gray-colored wells 268 indicate "hits" where the translocation value fell between 10% and 50%.
  • Row “E” on the 96 well plate being analyzed 266 shows a titration with a drug known to activate GFP-hGR translocation, dexamethasone.
  • This example screen used only two fluorescence channels. Two additional channels (Channels 3 263 and 4 264 are available for parallel analysis of other specific targets, cell processes, or cytotoxicity to create multiple parameter screens.
  • 279 for individual cells can be viewed separately, or summary data can be plotted.
  • the calculated results of a single parameter for each cell in a 96 well plate are shown in the panel labeled Graph 1 275.
  • the user can display the entire data set for a particular cell that is recalled from an existing database. Shown here are the image pair 276 and detailed fluorescence and mo ⁇ hometric data from a single cell (Cell #118, gray line 277).
  • the large graphical insert 278 shows the results of dexamethasone concentration on the translocation of GFP-hGR. Each point is the average of data from at least 200 cells.
  • EC 50 for dexamethasone in this assay is 2 nM.
  • FIG. 23 shows kinetic data for the dexamethasone- induced translocation of GFP-hGR in several cells within a single field.
  • Human HeLa cells transfected with GFP-hGR were treated with 100 nM dexamethasone and the translocation of GFP-hGR was measured over time in a population of single cells.
  • the graph shows the response of transfected cells 285, 286, 287. and 288 and non- transfected cells 289. These data also illustrate the ability to analyze cells with different expression levels.
  • Example 6 High-content screen of drug-induced apoptosis
  • Apoptosis is a complex cellular program that involves myriad molecular events and pathways. To understand the mechanisms of drug action on this process, it is essential to measure as many of these events within cells as possible with temporal and spatial resolution. Therefore, an apoptosis screen that requires little cell sample preparation yet provides an automated readout of several apoptosis-related parameters would be ideal.
  • a cell-based assay designed for the cell screening system has been used to simultaneously quantify several of the mo ⁇ hological, organellar, and macromolecular hallmarks of paclitaxel-induced apoptosis. Cell preparation.
  • the cells chosen for this study were mouse connective tissue fibroblasts (L-929; ATCC CCL-1) and a highly invasive glioblastoma cell line (SNB- 19; ATCC CRL-2219) (Welch et al., In Vitro Cell. Dev. Biol. 31 :610, 1995).
  • the day before treatment with an apoptosis inducing drug 3500 cells were placed into each well of a 96-well plate and incubated overnight at 37°C in a humidified 5% CO atmosphere.
  • the culture medium was removed from each well and replaced with fresh medium containing various concentrations of paclitaxel (0 - 50 ⁇ M) from a 20 mM stock made in DMSO.
  • DMSO DMSO
  • the maximal concentration of DMSO used in these experiments was 0.25%.
  • the cells were then incubated for 26 h as above.
  • each well received fresh medium containing 750 nM MitoTracker Red (Molecular Probes; Eugene, OR) and 3 ⁇ g/ml Hoechst 33342 DNA-binding dye (Molecular Probes) and was incubated as above for 20 min.
  • Each well on the plate was then washed with HBSS and fixed with 3.7% formaldehyde in HBSS for 15 min at room temperature.
  • the formaldehyde was washed out with HBSS and the cells were permeabilized for 90 s with 0.5% (v/v) Triton X-100, washed with HBSS, incubated with 2 U mf 1 Bodipy FL phallacidin (Molecular Probes) for 30 min, and washed with HBSS.
  • the wells on the plate were then filled with 200 ⁇ l HBSS, sealed, and the plate stored at 4°C if necessary.
  • the fluorescence signals from plates stored this way were stable for at least two weeks after preparation.
  • fluorescence reagents can be designed to convert this assay into a live cell high-content screen.
  • the average nuclear perimeter ( ⁇ m) was calculated by dividing the sum of the perimeters of all nuclei in a field by the number of nuclei detected in that field. Highly convoluted apoptotic nuclei had the largest nuclear perimeter values.
  • the average nuclear brightness was calculated by dividing the integrated intensity of the entire field of nuclei by the number of nuclei in that field. An increase in nuclear brightness was correlated with increased DNA content.
  • the average cellular brightness was calculated by dividing the integrated intensity of an entire field of cells stained with MitoTracker dye by the number of nuclei in that field. Because the amount of MitoTracker dye that accumulates within the mitochondria is proportional to the mitochondrial potential, an increase in the average cell brightness is consistent with an increase in mitochondrial potential.
  • Example 7 Protease induced translocation of a signaling enzyme containing a disease-associated sequence from cytoplasm to nucleus. Plasmid construct. A eukaryotic expression plasmid containing a coding sequence for a green fluorescent protein - caspase (Cohen (1997), Biochemical J.
  • the construct is used to transfect eukaryotic cells.
  • Cell preparation and transfection Cells are trypsinized and plated 24 h prior to transfection and incubated at 37°C and 5% CO . Transfections are performed by methods including, but not limited to calcium phosphate coprecipitation or lipofection. Cells are incubated with the calcium phosphate-DNA precipitate for 4-5 hours at 37°C and 5% CO , washed 3-4 times with DMEM to remove the precipitate, followed by the addition of C-DMEM. Lipofectamine transfections are performed in serum-free DMEM without antibiotics according to the manufacturer's instructions. Following a 2-3 hour incubation with the DNA-liposome complexes, the medium is removed and replaced with C-DMEM.
  • Caspase-GFP translocation kinetic data nuclei of transfected cells are first labeled with 5 ⁇ g/ml Hoechst 33342 (Molecular Probes) in C-DMEM for 20 minutes at 37°C and 5% CO 2 . Cells are washed once in Hank's Balanced Salt Solution (HBSS) followed by the addition of compounds that induce apoptosis. These compounds include, but are not limited to paclitaxel, staurosporine, ceramide, and tumor necrosis factor.
  • HBSS Hank's Balanced Salt Solution
  • transfected cells are first washed with DMEM and then incubated at 37°C and 5% CO for 1 h in the presence of 0 - 1000 nM compound in DMEM.
  • Cells are analyzed live or they are rinsed with HBSS, fixed for 15 min with 3.7% formaldehyde in HBSS, stained with Hoechst 33342, and washed before analysis.
  • Kinetic data are collected by acquiring fluorescence image pairs (Caspase-GFP and Hoechst 33342-labeled nuclei) from fields of living cells at 1 min intervals for 30 min after the addition of compound. Likewise, image pairs are obtained from each well of the fixed time point screening plates 1 h after the addition of compound. In both cases, the image pairs obtained at each time point are used to define nuclear and cytoplasmic regions in each cell. Translocation of Caspase-GFP is calculated by dividing the integrated fluorescence intensity of Caspase- GFP in the nucleus by the integrated fluorescence intensity of the chimera in the cytoplasm or as a nuclear-cytoplasmic difference of GFP fluorescence.
  • this translocation ratio is calculated from data obtained from at least 200 cells at each concentration of compound tested. Drug-induced translocation of Caspase-GFP from the cytoplasm to the nucleus is therefore correlated with an increase in the translocation ratio.
  • Molecular interaction libraries including, but not limited to those comprising putative activators or inhibitors of apoptosis-activated enzymes are use to screen the indicator cell lines and identify a specific ligand for the DAS, and a pathway activated by compound activity.
  • disease associated sequence bank(s) containing cDNA sequences suitable for transfection into mammalian cells can be used. Because every RADE or differential expression experiment generates up to several hundred sequences, it is possible to generate an ample supply of DAS.
  • information from primary sequence database searches can be used to place DAS into broad categories, including, but not limited to, those that contain signal sequences, seven trans-membrane motifs, conserved protease active site domains, or other identifiable motifs. Based on the information acquired from these sources, method types and indicator cell lines to be transfected are selected. A large number of motifs are already well characterized and encoded in the linear sequences contained within the large number genes in existing genomic databases. In one embodiment, the following steps are taken:
  • Information from the DAS identification experiment is used as the basis for selecting the relevant biological processes, (for example, look at the DAS from a tumor line for cell cycle modulation, apoptosis, metastatic proteases, etc.) 2) Sorting of DNA sequences or DAS by identifiable motifs (ie. signal sequences, 7- transmembrane domains, conserved protease active site domains, etc.) This initial grouping will determine fluorescent tagging strategies, host cell lines, indicator cell lines, and banks of bioactive molecules to be screened, as described supra. 3) Using well established molecular biology methods, ligate DAS into an expression vector designed for this pu ⁇ ose.
  • Generalized expression vectors contain promoters, enhancers, and terminators for which to deliver target sequences to the cell for transient expression. Such vectors may also contain antibody tagging sequences, direct association sequences, chromophore fusion sequences like GFP, etc. to facilitate detection when expressed by the host.
  • DAS containing vectors Transiently transfect cells with DAS containing vectors using standard transfection protocols including: calcium phosphate co-precipitation, liposome mediated, DEAE dextran mediated, polycationic mediated, viral mediated, or electroporation, and plate into microtiter plates or microwell arrays. Alternatively, transfection can be done directly in the microtiter plate itself. 5) Carry out the cell screening methods as described supra.
  • DAS shown to possess a motif(s) suggestive of transcriptional activation potential are utilized to identify novel steroid receptors.
  • Defining the fluorescent tags for this experiment involves identification of the nucleus through staining, and tagging the DAS by creating a GFP chimera via insertion of DAS into an expression vector, proximally fused to the gene encoding GFP.
  • a single chain antibody fragment with high affinity to some portion of the expressed DAS could be constracted using technology available in the art (Cambridge Antibody Technologies) and linked to a fluorophore (FITC) to tag the putative transcriptional activator/receptor in the cells.
  • FITC fluorophore
  • a eukaryotic expression plasmid containing a coding sequence for a green fluorescent protein - DAS chimera is prepared using GFP mutants.
  • the construct is used to transfect HeLa cells.
  • the plasmid when transfected into the host cell, produces a GFP fused to the DAS protein product, designated GFP- DASpp.
  • Cell preparation and transfection. HeLa cells are trypsinized and plated using
  • Transfections are performed by calcium phosphate coprecipitation or with Lipofectamine (Life Technologies).
  • the medium is replaced, prior to transfection, with DMEM containing 5% charcoal/dextran-treated FBS.
  • Cells are incubated with the calcium phosphate-DNA precipitate for 4-5 hours at 37°C and 5% CO , and washed 3-4 times with DMEM to remove the precipitate, followed by the addition of C-DMEM.
  • Lipofectamine transfections are performed in serum-free DMEM without antibiotics according to the manufacturer's instructions. Following a 2-3 hour incubation with the DNA-liposome complexes, the medium is removed and replaced with C-DMEM. All transfected cells in 96-well microtiter plates are incubated at 33°C and 5% CO 2 for 24-48 hours prior to drag treatment. Experiments are performed with the receptor expressed transiently in HeLa cells.
  • nuclei of transfected cells are first labeled with 5 ⁇ g/ml Hoechst 33342 (Molecular Probes) in C-DMEM for 20 minutes at 33°C and 5% CO 2 .
  • Cells are washed once in Hank's Balanced Salt Solution (HBSS).
  • HBSS Hank's Balanced Salt Solution
  • the cells are analyzed live or they are rinsed with HBSS, fixed for 15 min with 3.7% formaldehyde in HBSS, stained with Hoechst 33342, and washed before analysis.
  • image acquisition and analysis are performed using the cell screening system of the present invention.
  • the intracellular GFP-DASpp fluorescence signal is collected by acquiring fluorescence image pairs (GFP-DASpp and Hoechst 33342-labeled nuclei) from field cells.
  • the image pairs obtained at each time point are used to define nuclear and cytoplasmic regions in each cell. Data demonstrating dispersed signal in the cytoplasm would be consistent with known steroid receptors that are DNA transcriptional activators.
  • GFP-DASpp Screening for induction of GFP-DASpp translocation.
  • a screen of various ligands is performed using a series of steroid type ligands including, but not limited to: estrogen, progesterone, retinoids, growth factors, androgens, and many other steroid and steroid based molecules.
  • Image acquisition and analysis are performed using the cell screening system of the invention.
  • the intracellular GFP-DASpp fluorescence signal is collected by acquiring fluorescence image pairs (GFP-DASpp and Hoechst 33342-labeled nuclei) from fields cells.
  • the image pairs obtained at each time point are used to define nuclear and cytoplasmic regions in each cell.
  • Translocation of GFP-DASpp is calculated by dividing the integrated fluorescence intensity of GFP-DASpp in the nucleus by the integrated fluorescence intensity of the chimera in the cytoplasm or as a nuclear-cytoplasmic difference of GFP fluorescence.
  • a translocation from the cytoplasm into the nucleus indicates a ligand binding activation of the DASpp thus identifying the potential receptor class and action. Combining this data with other data obtained in a similar fashion using known inhibitors and modifiers of steroid receptors, would either validate the DASpp as a target, or more data would be generated from various sources.
  • a fluorescent protein biosensor of profilin membrane binding is prepared by labeling purified profilin (Federov et al.(1994), J. Molec. Biol. 241 :480-482; Lanbrechts et al. (1995), Eur. J. Biochem. 230:281-286) with a probe possessing a fluorescence lifetime in the range of 2-300 ns.
  • the labeled profilin is introduced into living indicator cells using bulk loading methodology and the indicator cells are treated with test compounds. Fluorescence anisotropy imaging microscopy (Gough and Taylor (1993), J. Cell Biol. 121 :1095-1107) is used to measure test- compound dependent movement of the fluorescent derivative of profilin between the cytoplasm and membrane for a period of time after treatment ranging from 0.1 s to 10 h.
  • Rho-RhoGDI complex translocation to the membrane In another embodiment, indicator cells are treated with test compounds and then fixed, washed, and permeabilized. The indicator cell plasma membrane, cytoplasm, and nucleus are all labeled with distinctly colored markers followed by immunolocahzation of Rho protein (Self et al. (1995), Methods in Enzymology 256:3-10; Tanaka et al. (1995), Methods in Enzymology 256:41-49) with antibodies labeled with a fourth color. Each of the four labels is imaged separately using the cell screening system, and the images used to calculate the amount of inhibition or activation of translocation effected by the test compound.
  • the images of the probes used to mark the plasma membrane and cytoplasm are used to mask the image of the immunological probe marking the location of intracellular Rho protein.
  • the integrated brightness per unit area under each mask is used to form a translocation quotient by dividing the plasma membrane integrated brightness/area by the cytoplasmic integrated brightness/area.
  • the percent translocation is calculated for each potential lead compound. -Arrestin translocation to the plasma membrane upon G-protein receptor activation.
  • the translocation of ⁇ -arrestin protein from the cytoplasm to the plasma membrane is measured in response to cell treatment.
  • living indicator cells containing luminescent domain markers are treated with test compounds and the movement of the ⁇ -arrestin marker is measured in time and space using the cell screening system of the present invention.
  • the indicator cells contain luminescent markers consisting of a green fluorescent protein ⁇ -anestin (GFP- ⁇ -anestin) protein chimera (Barak et al. (1997), J. Biol. Chem. 272:27497-27500; Daaka et al. (1998), J. Biol. Chem.
  • the indicator cells that is expressed by the indicator cells through the use of transient or stable cell transfection and other reporters used to mark cytoplasmic and membrane domains.
  • the domain marker molecules partition predominately in the plasma membrane or in the cytoplasm. In the high-content screen, these markers are used to delineate the cell cytoplasm and plasma membrane in distinct channels of fluorescence.
  • the indicator cells are treated with a test compound, the dynamic redistribution of the GFP- ⁇ -arrestin is recorded as a series of images over a time scale ranging from 0.1 s to 10 h. In a prefened embodiment, the time scale is 1 h.
  • Each image is analyzed by a method that quantifies the movement of the GFP- ⁇ -arrestin protein chimera between the plasma membrane and the cytoplasm.
  • the images of the probes used to mark the plasma membrane and cytoplasm are used to mask the image of the GFP- ⁇ -arrestin probe marking the location of intracellular GFP- ⁇ -anestin protein.
  • the integrated brightness per unit area under each mask is used to form a translocation quotient by dividing the plasma membrane integrated brightness/area by the cytoplasmic integrated brightness/area. By comparing the translocation quotient values from control and experimental wells, the percent translocation is calculated for each potential lead compound.
  • the output of the high- content screen relates quantitative data describing the magnitude of the translocation within a large number of individual cells that have been treated with test compounds of interest. Translocation between the endoplasmic reticulum and the Golgi:
  • an endoplasmic reticulum to Golgi translocation high- content screen the translocation of a VSVG protein from the ts045 mutant strain of vesicular stomatitis virus (Ellenberg et al. (1997), J. Cell Biol. 138:1193-1206; Presley et al. (1997) Nature 389:81-85) from the endoplasmic reticulum to the Golgi domain is measured in response to cell treatment.
  • indicator cells containing luminescent reporters are treated with test compounds and the movement of the reporters is measured in space and time using the cell screening system of the present invention.
  • the indicator cells contain luminescent reporters consisting of a GFP-VSVG protein chimera that is expressed by the indicator cell through the use of transient or stable cell transfection and other domain markers used to measure the localization of the endoplasmic reticulum and Golgi domains.
  • the GFP-VSVG protein chimera molecules are partitioned predominately in the endoplasmic reticulum.
  • domain markers of distinct colors used to delineate the endoplasmic reticulum and the Golgi domains in distinct channels of fluorescence.
  • the dynamic redistribution of the GFP-VSVG protein chimera is recorded as a series of images over a time scale ranging from 0.1 s to 10 h. Each image is analyzed by a method that quantifies the movement of the GFP-VSVG protein chimera between the endoplasmic reticulum and the Golgi domains. To do this calculation, the images of the probes used to mark the endoplasmic reticulum and the Golgi domains are used to mask the image of the GFP-VSVG probe marking the location of intracellular GFP- VSVG protein.
  • the integrated brightness per unit area under each mask is used to form a translocation quotient by dividing the endoplasmic reticulum integrated brightness/area by the Golgi integrated brightness/area. By comparing the translocation quotient values from control and experimental wells, the percent translocation is calculated for each potential lead compound.
  • the output of the high-content screen relates quantitative data describing the magnitude of the translocation within a large number of individual cells that have been treated with test compounds of interest at final concentrations ranging from 10 ⁇ 12 M to 10 "3 M for a period ranging from 1 min to 10 h.
  • Induction and inhibition of organellar function Intracellular microtubule stability.
  • an automated method for identifying compounds that modify microtubule structure is provided.
  • indicator cells are treated with test compounds and the distribution of luminescent microtubule-labeling molecules is measured in space and time using a cell screening system, such as the one disclosed above.
  • the luminescent microtubule-labeling molecules may be expressed by or added to the cells either before, together with, or after contacting the cells with a test compound.
  • living cells express a luminescently labeled protein biosensor of microtubule dynamics, comprising a protein that labels microtubules fused to a luminescent protein.
  • Appropriate microtubule- labeling proteins for this aspect of the invention include, but are not limited to ⁇ and ⁇ tubulin isoforms, and MAP4.
  • Preferred embodiments of the luminescent protein include, but are not limited to green fluorescent protein (GFP) and GFP mutants.
  • the method involves transfecting cells with a microtubule labeling luminescent protein, wherein the microtubule labeling protein can be, but is not limited to, ⁇ -tubulin, ⁇ -tubulin, or micro tubule-associated protein 4 (MAP4).
  • a microtubule labeling luminescent protein can be, but is not limited to, ⁇ -tubulin, ⁇ -tubulin, or micro tubule-associated protein 4 (MAP4).
  • MAP4 micro tubule-associated protein 4
  • MAP4 is fused to a modified version of the Aequorea victoria green fluorescent protein (GFP).
  • GFP Aequorea victoria green fluorescent protein
  • a DNA construct has been made which consists of a fusion between the EGFP coding sequence (available from Clontech) and the coding sequence for mouse MAP4. (Olson et al., (1995), J. Cell Biol. 130(3): 639-650).
  • MAP4 is a ubiquitous microtubule-associated protein that is known to interact with microtubules in inte ⁇ hase as well as mitotic cells (Olmsted and Murofushi, (1993), MAP4. In "Guidebook to the Cytoskeleton and Motor Proteins.” Oxford University Press. T. Kreis and R.
  • the luminescently labeled protein biosensor of microtubule dynamics is expressed, isolated, and added to the cells to be analyzed via bulk loading techniques, such as microinjection, scrape loading, and impact-mediated loading.
  • bulk loading techniques such as microinjection, scrape loading, and impact-mediated loading.
  • ⁇ and ⁇ tubulin isoforms, MAP4, MAP2 and/or tau can all be used.
  • the protein biosensor is expressed by the cell, and the cell is subsequently contacted with a luminescent label, such as a labeled antibody, that detects the protein biosensor, endogenous levels of a protein antigen, or both.
  • a luminescent label that detects ⁇ and ⁇ tubulin isoforms, MAP4, MAP2 and/or tau, can be used.
  • GFP mutants are available, all of which would be effective in this invention, including, but not limited to, GFP mutants which are commercially available
  • the MAP4 construct has been introduced into several mammalian cell lines (BHK-21, Swiss 3T3, HeLa, HEK 293, LLCPK) and the organization and localization of tubulin has been visualized in live cells by virtue of the GFP fluorescence as an indicator of MAP4 localization.
  • the construct can be expressed transiently or stable cell lines can be prepared by standard methods. Stable HeLa cell lines expressing the
  • EGFP-MAP4 chimera have been obtained, indicating that expression of the chimera is not toxic and does not interfere with mitosis.
  • Possible selectable markers for establishment and maintenance of stable cell lines include, but are not limited to the neomycin resistance gene, hygromycin resistance gene, zeocin resistance gene, puromycin resistance gene, bleomycin resistance gene, and blastacidin resistance gene.
  • microtubule drags such as paclitaxel, nocodazole, vincristine, or vinblastine.
  • the present method provides high-content and combined high throughput-high content cell-based screens for anti-microtubule drags, particularly as one parameter in a multi-parametric cancer target screen.
  • the EGFP-MAP4 construct used herein can also be used as one of the components of a high-content screen that measures multiple signaling pathways or physiological events.
  • a combined high throughput and high content screen is employed, wherein multiple cells in each of the locations containing cells are analyzed in a high throughput mode, and only a subset of the locations containing cells are analyzed in a high content mode.
  • the high throughput screen can be any screen that would be useful to identify those locations containing cells that should be further analyzed, including, but not limited to, identifying locations with increased luminescence intensity, those exhibiting expression of a reporter gene, those undergoing calcium changes, and those undergoing pH changes.
  • the present invention may be applied to clinical diagnostics, the detection of chemical and biological warfare weapons, and the basic research market since fundamental cell processes, such as cell division and motility, are highly dependent upon microtubule dynamics.
  • Image data can be obtained from either fixed or living indicator cells.
  • mo ⁇ hometric data from each of the images obtained the following method of analysis is used:
  • Microtubule mo ⁇ hology is defined using a set of classifiers to quantify aspects of microtubule shape, size, aggregation state, and polymerization state. These classifiers can be based on approaches that include co-occurrence matrices, texture measurements, spectral methods, structural methods, wavelet transforms, statistical methods, or combinations thereof.
  • a classifier to quantify microtubule length and width using edge detection methods such as that discussed in Kolega et al. ((1993). Biolmaging 1 : 136- 150), which discloses a non-automated method to determine edge strength in individual cells), to calculate the total edge strength within each cell.
  • the total edge strength can be divided by the cell area to give a "microtubule mo ⁇ hology" value.
  • Large microtubule mo ⁇ hology values are associated with strong edge strength values and are therefore maximal in cells containing distinct microtubule structures.
  • small microtubule mo ⁇ hology values are associated with weak edge strength and are minimal in cells with depolymerized microtubules.
  • the physiological range of microtubule mo ⁇ hology values is set by treating cells with either the microtubule stabilizing drag paclitaxel (10 ⁇ M) or the microtubule depolymerizing drag nocodazole (10 ⁇ g/ml).
  • a classifier to quantify microtubule depolymerization using a measure of image texture 4.
  • a classifier to quantify apparent interconnectivity, or branching (or both), of the microtubules.
  • kits for analyzing microtubule stability, comprising an expression vector comprising a nucleic acid that encodes a microtubule labeling protein and instractions for using the expression vector for carrying out the methods described above.
  • the expression vector further comprises a nucleic acid that encodes a luminescent protein, wherein the microtubule binding protein and the luminescent protein thereof are expressed as a fusion protein.
  • the kit may contain an antibody that specifically binds to the microtubule-labeling protein.
  • the kit includes cells that express the microtubule labeling protein.
  • the cells are transfected with the expression vector.
  • kits further contain a compound that is known to disrupt microtubule structure, including but not limited to curacin, nocodazole, vincristine, or vinblastine.
  • the kits further comprise a compound that is known to stabilize microtubule structure, including but not limited to taxol (paclitaxel), and discodermolide.
  • the present invention comprises a machine readable storage medium comprising a program containing a set of instractions for causing a cell screening system to execute the disclosed methods for analyzing microtubule stability
  • the cell screening system comprises an optical system with a stage adapted for holding a plate containing cells, a digital camera, a means for directing fluorescence or luminescence emitted from the cells to the digital camera, and a computer means for receiving and processing the digital data from the digital camera.
  • Peroxisomes are involved in a number of metabolic processes, and are essential for de-toxification, ⁇ -oxidation of lipid, and metabolism of peroxide and superoxide. Peroxisomes use molecular oxygen to produce hydrogen peroxide, and also contain catalase, which uses hydrogen peroxide to oxidize other products such as alcohols and phenols. Additionally, peroxisomes are involved in fatty acid breakdown, ultimately producing acteylCoA. Peroxisomes and peroxisomal proteins have been implicated in a number of metabolic diseases, such as Zelleweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. These are all lethal conditions that are characterized by severe mental retardation.
  • Peroxisome detection has also been accomplished by using cells transfected with chimeric constructs consisting of -an auto-fluorescent protein coupled to a peroxisomal targeting signal, followed by visualization of the cell to detect the chimeric protein, and thus the peroxisome.
  • chimeric constructs consisting of -an auto-fluorescent protein coupled to a peroxisomal targeting signal
  • These methods permit analysis of peroxisome movement over time, but are not quantitative nor automated, and thus are not amenable to high throughput and/or high content drag screening. Also, apart from manually counting each peroxisome, there is no current method available to fluorescently quantitate and evaluate peroxisome proliferation.
  • the present invention provides automated methods, computer readable storage media, and kits for analyzing and quantifying changes in peroxisome number and distribution in response to a stimulus in any peroxisome-containing cell type. Such methods are usfeful in a variety of situations, including but not limited to: (1) identifying compounds that are toxic to hepatocytes or that inhibit the effects of hepatocyte toxins. Hepatocytes are naturally enriched in peroxisomes, and certain toxins could effect the number, size or distribution of this organelle. - Bentley et al., Food Chem Toxicol, 31 :857-970 (1993)- Steir et al., Differentiation 64:55-66 (1998); James et al., Toxicology Letters 102-103:91-96 (1998)).
  • the methods described herein could also be used in screens designed to assess microtubule integrity.
  • peroxisomes are distributed stochastically throughout the cell coincident with microtubules. (Wiemer et al., J. Cell Biol. 136:71-80 (1997)). If microtubules are disrupted or depolymerized, the change should be reflected in the observed peroxisomal distribution.
  • the methods of the present invention can also be used to monitor the differentiation state of adipocytes. Peroxisome number and distribution are altered during adipocyte differentiation.
  • the methods of the present invention can be used to analyze changes in peroxisome number and distribution in adipocytes, which are measures of adipocyte differentiation. Such methods would be useful for screens designed to study fatty acid metabolism, as well as for identifying compounds to treat and/or prevent obesity and diabetes.
  • the invention comprises an automated method for analyzing peroxisome proliferation or distribution in a cell, comprising: a. providing an array of locations containing multiple cells, wherein the cells possess a luminescent reporter molecule, wherein the luminescent reporter molecule comprises a peroxisome-targeting sequence; b. scanning each of the locations containing multiple cells to obtain luminescent signals from the luminescent reporter molecules; c. converting the luminescent signals into digital data; and d. utilizing the digital data to automatically make measurements, wherein the measurements are used to automatically calculate changes in the number or distribution of the luminescent reporter molecules within the cell, and wherein the calculated changes in the number or distribution of the luminescent reporter molecules within the cell correlates with changes in peroxisome number or distribution.
  • the phrase "the cells possess a luminescent reporter molecules” means that the cells express one or more luminescent reporter molecules, which may be expressed as a luminescent reporter molecule by the cells, added to the cells as a luminescent reporter molecule, or luminescently labeled by contacting the cell with a luminescently labeled molecule such as a dye or antibody, that binds to the reporter molecule.
  • the luminescent reporter molecule can be expressed by the cells, or added to the cell either before or after treatment with a candidate compound.
  • Any cell type that possess peroxisomes may be used in carrying out the methods of the present invention.
  • a luminescent reporter that labels the whole cell includes, but is not limited to, those reporter molecules that label cytoplasmic components, the plasma membrane, cytoskeletal components, and volume markers such as dextrans.
  • a peroxisome-targeting signal comprises any amino acid sequence that can be used to target the reporter molecule to peroxisomes, including but not limited to LSKL (SEQ ID NO:l) (Wiemer, et al., J. Cell Biol. 136:71-80 (1997)); SNL (SEQ ID NO:2) (Amery, L. et al. Biochem J. 336:367-371 (1998)); LSNL (SEQ ID NO:3) ; KSNL (SEQ ID NO:4).
  • LSKL SEQ ID NO:l
  • SNL SEQ ID NO:2
  • LSNL SEQ ID NO:3
  • KSNL SEQ ID NO:4
  • the luminescent reporter molecule may be any luminescent protein that can be visualized by using a cell screening system.
  • an autofluorescent protein such as a green fluorescent protein, or derivatives thereof (including color variants) is used.
  • the method further comprises contacting the cells with a test agent prior to scanning, and/or contacting the cells with a nucleus-specific second luminescent reporter molecule, including but not limited to 4',6-Diamidino-2- phenylindole (DAPI ), Hoechst dyes such as Hoechst 33342 (“Hoechst”), or propidium iodide (PI) (Molecular Probes).
  • test agents include, but are not limited to organisms, macromolecules, or organic or inorganic molecules.
  • the measurements comprise determining one or more of the following: a. a total or average luminescence intensity of the nucleus-specific second luminescent reporter molecule; b. a total or average luminescence intensity of the luminescent reporter molecule outside the cell nucleus; c. an area of the cell nucleus; d. an area of the cell cytoplasm; e. a number of peroxisomes per cell; f. a distribution of peroxisomes in the cell; or g. a total or average luminescence intensity per cellular area attributed to the peroxisomes in the cell.
  • the method further comprises calculating changes in one or more of the above measurements, and/or segmenting the image of the cell nuclei.
  • the scanning of the locations can be conducted in a high throughput mode, followed by selective scanning of a subset of the cells in a high content mode to obtain luminescent signals from the luminescent reporter molecules in the cells.
  • sub-regions of the anay of locations containing multiple cells can be sampled multiple times at intervals to provide kinetic measurement of peroxisome proliferation or changes in peroxisome distribution.
  • the present invention provides machine readable storage media comprising a program containing a set of instractions for causing a cell screening system to analyze peroxisome proliferation or distribution in a cell, wherein the cell screening system comprises an optical system with a stage adapted for holding a plate containing cells, a digital camera, a means for directing luminescence from the cells to the digital camera, and a computer means for receiving and processing the digital data from the digital camera.
  • kits for identifying agents that modify peroxisomal proliferation or distribution in a cell comprising a luminescent reporter molecule comprising a peroxisome-targeting sequence, and instractions for using the luminescent reporter molecule to analyze peroxisome proliferation or distribution in a cell.
  • the kit further comprises a nucleus- specific second luminescent reporter molecule, and/or a further luminescent reporter molecule to label the whole cell, and/or a control compound that is known to modify peroxisomal proliferation or distribution.
  • control compounds include, but are not limited to colchicine, nocodazole, prostaglandin, hydrogen peroxide, ethanol, clofibrates, thiazolidene diones, and retinoic acid
  • reporter molecules cDNAs encoding three green fluorescent protein (GFP) variants, sgl2, sg25 and sg50, (U.S. 6,027,881, inco ⁇ orated by reference herein in its entirety) were used as PCR templates for amplification with an antisense primer designed to encode 4 new amino acids at the carboxy terminus of GFP required for protein targeting to peroxisomes (LSKL) (SEQ ID NO:l).
  • the chimeras were designated PX12, PX25, and PX50, indicating the fusion to GFP sgl2, sg25, and sg50 respectively.
  • Previous research has demonstrated that the LSKL sequence alone is sufficient to direct GFP specifically to peroxisomes (Wiemer, et al., J. Cell Biol. 136: pg 71-80 (1997)).
  • HepG2 (hepatocarcinoma) and 3T3-L1 (fibroblast) cell lines were used in conjunction with the PX25 marker to monitor peroxisome distribution in response to toxin exposure, or during adipocyte differentiation, respectively.
  • Cells were transiently transfected using standard liposome-mediated techniques and 1-5 ⁇ g of highly purified expression vector DNA. Following transfection, cells were allowed to recover and express protein for 18-36 hours prior to observation or drug treatment. In some cases, stable neomycin-resistant cell lines were selected that continuously expressed the PX25 marker over several generations of cells.
  • Ll cells were seeded onto glass coverslips and grown to 80% confluency. Cells were then transfected with the PX-25 expression vector and allowed to express the peroxisomal marker for 24 hours prior to further treatment. At this point, cells were at complete confluency. In some cases, clonal cells lines were selected using standard techniques employing drag resistance genes inco ⁇ orated into the expression vector.
  • Adipocyte differentiation can be promoted using two similar techniques. One method allows the cells to naturally differentiate by leaving them confluent for 1-2 weeks. A second method involves adding differentiation supplements to the growth medium (10 ⁇ g/ml insulin, 10 ⁇ M dexamethasone, and 0.5 mM l-methyl-3- isobutylxanthine (IBMX)) in order to decrease the time frame of differentiation to 4-7 days (Toscani, et al, J. Biol. Chem. 265:5722-30 (1990)). Following differentiation, cells were fixed in 3.7% formaldehyde and labeled with Hoechst dye to identify the position of the nucleus, and BODIPYTM-665 (Molecular Probes, Eugene OR) to monitor lipid uptake.
  • IBMX 0.5 mM l-methyl-3- isobutylxanthine
  • Peroxisome proliferation was analyzed during this process by measuring the fluorescence intensity of the PX25 fluorescent reporter, the actual number of peroxisomes, as well as their intracellular distribution.
  • a similar approach was taken in PX-25 transfected HepG2 cells in order to assay for alterations in peroxisome number, size, distribution or fluorescent intensity after treatment with toxins, differentiation agents, or peroxisome proliferator activated receptor (PPAR) agonists. Following transfection and drug treatment, cells were either fixed with formaldehyde or observed live using the fluorescent peroxisome marker.
  • Peroxisomes are localized within the cell in a microtubule-dependent manner. (Wiemer et al., J. Cell Biol. 136:71-80 (1997)). When microtubule integrity is compromised by de-polymerizing drags such as colchicine or nocodazole, peroxisome distribution in the cell is altered. Under such conditions, peroxisomes cease to undergo directed motion and are re-distributed to a predominantly peri-nuclear pattern.
  • Cells were transfected with the PX-25 expression vector as previously described and allowed to express protein for 24 hours prior to drag treatment. After treatment with microtubule-activating compounds, nuclear DNA was labeled with Hoechst and live cells were assayed for changes in peroxisome distribution. Using fixed cells, multi-parameter assays can also be conducted with the PX25 marker using additional organelle-specific dyes for mitochondria or cytoskeletal elements such as actin microfilaments. Alterations in peroxisome distribution were determined by observing the intensity of fluorescence adjacent to the nucleus in drag treated cells relative to controls.
  • Swiss 3T3 cells were liposome transfected with the PX-25 expression vector and incubated under normal growth conditions for 24 hours prior to challenge with 10 ⁇ M nocodazole for up to 60 minutes (0, 30, and 60 minutes). After appropriate incubation, the cells were fixed in 3.7% formaldehyde and permeabilized with 0.5% Triton X-100 for 2 minutes and peroxisome distribution was analyzed.
  • Cytoplasmic Mask A cytoplasmic mask can be created if cells are uniformly spread through the sample, without forming clumps or touching each other. The whole cell is identified by labeling it with a fluorescent marker such as phalloidin or chloromethylfluorescein diacetate (CMFDA). Using an appropriate filter set, an image of the fluorescent cell is acquired, and adaptive thresholding is applied to produce the whole cell mask.
  • CMFDA chloromethylfluorescein diacetate
  • a nuclear mask can be made by labeling the cells with DNA-specific dyes, including but not limited to Hoescht or DAPI. This is followed by fluorescent nuclei image acquisition using an appropriate filter set, and by application of adaptive theresholding to delineate individual nuclei and to effectively separate this cellular compartment from the cytoplasm.
  • the cytoplasmic mask is created by subtracting the nuclear mask from the whole cell mask.
  • Cytoplasmic Approximation In the absence of a distinctly outlined (defined) cytoplasmic mask (due, for example, to high cell density within a sample or cell clustering), an approximation of the cytoplasmic mask is used.
  • a nuclear mask is created, by labeling the nucleus with a DNA-specific dye such as Hoechst or DAPI.
  • a DNA-specific dye such as Hoechst or DAPI.
  • an image of a fluorescent nucleus is acquired and adaptive thresholding is applied to delineate individual nuclei and to effectively separate this cellular compartment from the cytoplasm.
  • the nuclear mask is then dilated (expanded) by 2-3 pixels, thereby extending it into the cytoplasmic region.
  • the approximation of the cytoplasmic mask is created. This mask can then be applied to an image of the fluorescently labeled peroxisomes and the fluorescence intensity within the cytoplasm under the mask can be measured.
  • Peroxisome Count Peroxisomes have a very uniform size and fluorescent intensity, which is especially trae in stable cell lines prepared by clonal isolation. Preliminary image analysis indicates that the appropriate threshold control can reproducibly identify the majority of peroxisomes within a single cell. The peroxisomes can then be counted using the appropriate object classifiers, eliminating dim objects or inappropriately sized objects. For clonal cell lines, an estimation of peroxisome number per cell can be derived by dividing the total number of peroxisomes counted within a field by the total number of nuclei identified using Hoechst or DAPI labeling.
  • the peroxisome label is used in conjunction with a second whole-cell marker
  • the total fluorescence intensity per cellular area attributed to the peroxisomes can be measured within the mask provided by the whole-cell marker.
  • the whole-cell marker could consist of a second GFP, a nonspecific cytoplasmic dye, or a marker that de-limits the cell periphery.
  • dynamic thresholding can be applied to the image to approximate the entire cell area.
  • the mask generated by this process can then be applied to the fluorescent image obtained for the labeled peroxisomes to obtain a measurement for peroxisome abundance within the cell based on the integrated fluorescence intensity.
  • the PX25 peroxisome marker was successfully expressed in a variety of standard cell types, including LLCPK, COS-1, CHO, BHK, and 3T3 cells. Peroxisome distribution was analyzed in living primary hepatocytes and HepG2 cells, as well as in living 3T3-L1 cells during adipocyte differentiation.
  • peroxisome distribution in primary hepatocytes, cultured hepatic carcinoma cells, and differentiating 3T3-L1 cells further demonstrated that fluorescently labeled peroxisomes can serve as indicators of peroxisome proliferation and/or adipocyte differentiation.
  • Peroxisome number and concommitant fluorescence intensity increased as much as 10-fold during the drag-induced differentiation of 3T3- Ll cells to adipocytes.
  • Hep G2 cells were cultured on coverslips and liposome transfected with the PX-25 expression vector. Following transfection, cells were incubated under normal culture conditions. They were then treated with a variety of toxic compounds that would potentially induce peroxisome proliferation, including 0.1% H2O2 and 0.5% ethanol. Peroxisome proliferation was observed over time in response to these treatments.
  • the methods described here provide the ability to automatically monitor and quantify peroxisome number and distribution in living cells, allowing time course analyses and eliminating the need for fixation and processing of plates.
  • the availability of color variants of the luminescent markers also opens the possibility of combining the assay for changes in peroxisome number and/or distribution with additional assays, including but not limited to those described herein for multi -parameter analyses.
  • peroxisome distribution can be combined in a multi-paramenter assay with lipid uptake to monitor adipocyte differentiation.
  • Various other multi- parameter assays, combining methods disclosed herein and elsewhere, can also be utilized.
  • High-content screens involving the functional localization of macromolecules Within this class of high-content screen, the functional localization of macromolecules in response to external stimuli is measured within living cells.
  • Glycolytic enzyme activity regulation In a prefened embodiment of a cellular enzyme activity high-content screen, the activity of key glycolytic regulatory enzymes are measured in treated cells. To measure enzyme activity, indicator cells containing luminescent labeling reagents are treated with test compounds and the activity of the reporters is measured in space and time using cell screening system of the present invention.
  • the reporter of intracellular enzyme activity is fractose-6- phosphate, 2-kinase/fractose-2,6-bisphosphatase (PFK-2), a regulatory enzyme whose phosphorylation state indicates intracellular carbohydrate anabolism or catabolism
  • the indicator cells contain luminescent reporters consisting of a fluorescent protein biosensor of PFK-2 phosphorylation.
  • the fluorescent protein biosensor is constracted by introducing an environmentally sensitive fluorescent dye near to the known phosphorylation site of the enzyme (Deprez et al. (1997), supra; Giuliano et al. (1995), supra).
  • the dye can be of the ketocyanine class (Kessler and Wolfbeis (1991), Spectrochimica Ada 47A:187-192 ) or any class that contains a protein reactive moiety and a fluorochrome whose excitation or emission spectrum is sensitive to solution polarity.
  • the fluorescent protein biosensor is introduced into the indicator cells using bulk loading methodology.
  • Living indicator cells are treated with test compounds, at final concentrations ranging from 10 "12 M to 10 "3 M for times ranging from 0.1 s to 10 h.
  • ratio image data are obtained from living treated indicator cells by collecting a spectral pair of fluorescence images at each time point. To extract mo ⁇ hometric data from each time point, a ratio is made between each pair of images by numerically dividing the two spectral images at each time point, pixel by pixel. Each pixel value is then used to calculate the fractional phosphorylation of PFK-2. At small fractional values of phosphorylation, PFK-2 stimulates carbohydrate catabolism. At high fractional values of phosphorylation, PFK-2 stimulates carbohydrate anabolism.
  • Protein kinase A activity and localization of subunits are measured in response to treatment with test compounds.
  • the indicator cells contain luminescent reporters including a fluorescent protein biosensor of PKA activation.
  • the fluorescent protein biosensor is constracted by introducing an environmentally sensitive fluorescent dye into the catalytic subunit of PKA near the site known to interact with the regulatory subunit of PKA (Harootunian et al. (1993), Mol Biol of the Cell 4:993-1002; Johnson et al. (1996), Cell 85: 149-158; Giuliano et al. (1995), supra).
  • the dye can be of the ketocyanine class (Kessler, and Wolfbeis (1991), Spectrochimica Ada 47A: 187-192) or any class that contains a protein reactive moiety and a fluorochrome whose excitation or emission spectrum is sensitive to solution polarity.
  • the fluorescent protein biosensor of PKA activation is introduced into the indicator cells using bulk loading methodology.
  • living indicator cells are treated with test compounds, at final concentrations ranging from 10 " M to 10 " M for times ranging from 0.1 s to 10 h.
  • ratio image data are obtained from living treated indicator cells. To extract biosensor data from each time point, a ratio is made between each pair of images, and each pixel value is then used to calculate the fractional activation of PKA (e.g., separation of the catalytic and regulatory subunits after cAMP binding). At high fractional values of activity, PFK-2 stimulates biochemical cascades within the living cell.
  • indicator cells containing luminescent reporters are treated with test compounds and the movement of the reporters is measured in space and time using the cell screening system.
  • the indicator cells contain luminescent reporters consisting of domain markers used to measure the localization of the cytoplasmic and nuclear domains.
  • the dynamic redistribution of a PKA fluorescent protein biosensor is recorded intracellularly as a series of images over a time scale ranging from 0.1 s to 10 h. Each image is analyzed by a method that quantifies the movement of the PKA between the cytoplasmic and nuclear domains.
  • the images of the probes used to mark the cytoplasmic and nuclear domains are used to mask the image of the PKA fluorescent protein biosensor.
  • the integrated brightness per unit area under each mask is used to form a translocation quotient by dividing the cytoplasmic integrated brightness/area by the nuclear integrated brightness/area.
  • the percent translocation is calculated for each potential lead compound.
  • the output of the high-content screen relates quantitative data describing the magnitude of the translocation within a large number of individual cells that have been treated with test compound in the concentration range of 10 "12 M to 10 "3 M. High-content screens involving the induction or inhibition of gene expression RNA-based fluorescent biosensors
  • Cytoskeletal protein transcription and message localization Regulation of the general classes of cell physiological responses including cell-substrate adhesion, cell-cell adhesion, signal transduction, cell-cycle events, intermediary and signaling molecule metabolism, cell locomotion, cell-cell communication, and cell death can involve the alteration of gene expression. High-content screens can also be designed to measure this class of physiological response.
  • the reporter of intracellular gene expression is an oligonucleotide that can hybridize with the target mRNA and alter its fluorescence signal.
  • the oligonucleotide is a molecular beacon (Tyagi and Kramer (1996) Nat. Biotechnol 14:303-308), a luminescence-based reagent whose fluorescence signal is dependent on intermolecular and intramolecular interactions.
  • the fluorescent biosensor is constracted by introducing a fluorescence energy transfer pair of fluorescent dyes such that there is one at each end (5' and 3') of the reagent.
  • the dyes can be of any class that contains a protein reactive moiety and fluorochromes whose excitation and emission spectra overlap sufficiently to provide fluorescence energy transfer between the dyes in the resting state, including, but not limited to, fluorescein and rhodamine (Molecular Probes, Inc.).
  • fluorescein and rhodamine Molecular Probes, Inc.
  • a portion of the message coding for ⁇ -actin (Kislauskis et al. (1994), J. Cell Biol. 127:441-451 ; McCann et al. (1997), Proc. Natl. Acad. Sci.
  • living indicator cells are treated with test compounds, at final concentrations ranging from 10 "12 M to 10 ⁇ 3 M for times ranging from 0.1 s to 10 h.
  • ratio image data are obtained from living treated indicator cells. To extract mo ⁇ hometric data from each time point, a ratio is made between each pair of images, and each pixel value is then used to calculate the fractional hybridization of the labeled nucleotide. At small fractional values of hybridization little expression of ⁇ -actin is indicated. At high fractional values of hybridization, maximal expression of ⁇ -actin is indicated. Furthermore, the distribution of hybridized molecules within the cytoplasm of the indicator cells is also a measure of the physiological response of the indicator cells.
  • Cell surface binding of a ligand Labeled insulin binding to its cell surface receptor in living cells Cells whose plasma membrane domain has been labeled with a labeling reagent of a particular color are incubated with a solution containing insulin molecules (Lee et al. (1997), Biochemistry 36:2701-2708; Martinez-Zaguilan et al. (1996), Am. J. Physiol 270:C1438-C1446) that are labeled with a luminescent probe of a different color for an appropriate time under the appropriate conditions. After incubation, unbound insulin molecules are washed away, the cells fixed and the distribution and concentration of the insulin on the plasma membrane is measured. To do this, the cell membrane image is used as a mask for the insulin image.
  • the integrated intensity from the masked insulin image is compared to a set of images containing known amounts of labeled insulin.
  • the amount of insulin bound to the cell is determined from the standards and used in conjunction with the total concentration of insulin incubated with the cell to calculate a dissociation constant or insulin to its cell surface receptor.
  • Whole cell labeling is accomplished by labeling cellular components such that dynamics of cell shape and motility of the cell can be measured over time by analyzing fluorescence images of cells.
  • small reactive fluorescent molecules are introduced into living cells. These membrane-permeant molecules both diffuse through and react with protein components in the plasma membrane. Dye molecules react with intracellular molecules to both increase the fluorescence signal emitted from each molecule and to entrap the fluorescent dye within living cells. These molecules include reactive chloromethyl derivatives of aminocoumarins, hydroxycoumarins, eosin diacetate, fluorescein diacetate, some Bodipy dye derivatives, and tetramethylrhodamine. The reactivity of these dyes toward macromolecules includes free primary amino groups and free sulfhydryl groups.
  • the cell surface is labeled by allowing the cell to interact with fluorescently labeled antibodies or lectins (Sigma Chemical Company, St. Louis, MO) that react specifically with molecules on the cell surface.
  • fluorescently labeled antibodies or lectins Sigma Chemical Company, St. Louis, MO
  • Cell surface protein chimeras expressed by the cell of interest that contain a green fluorescent protein, or mutant thereof, component can also be used to fluorescently label the entire cell surface.
  • labeling the whole plasma membrane employs some of the same methodology described above for labeling the entire cells.
  • Luminescent molecules that label the entire cell surface act to delineate the plasma membrane.
  • subdomains of the plasma membrane, the extracellular surface, the lipid bilayer, and the intracellular surface can be labeled separately and used as components of high content screens.
  • the extracellular surface is labeled using a brief treatment with a reactive fluorescent molecule such as the succinimidyl ester or iodoacetamde derivatives of fluorescent dyes such as the fluoresceins, rhodamines, cyanines, and Bodipys.
  • the extracellular surface is labeled using fluorescently labeled macromolecules with a high affinity for cell surface molecules.
  • fluorescently labeled lectins such as the fluorescein, rhodamine, and cyanine derivatives of lectins derived from jack bean (Con A), red kidney bean (erythroagglutinin PHA-E), or wheat germ.
  • fluorescently labeled antibodies with a high affinity for cell surface components are used to label the extracellular region of the plasma membrane. Extracellular regions of cell surface receptors and ion channels are examples of proteins that can be labeled with antibodies.
  • the lipid bilayer of the plasma membrane is labeled with fluorescent molecules.
  • fluorescent molecules include fluorescent dyes attached to long chain hydrophobic molecules that interact strongly with the hydrophobic region in the center of the plasma membrane lipid bilayer. Examples of these dyes include the PKH series of dyes (U.S. 4,783,401, 4,762701, and 4,859,584; available commercially from Sigma Chemical Company, St.
  • fluorescent phospholipids such as nitrobenzoxadiazole glycerophosphoethanolamine and fiuorescein-derivatized dihexadecanoylglycerophosphoetha-nolamine, fluorescent fatty acids such as 5-butyl- 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-3-nonanoic acid and 1-pyrenedecanoic acid (Molecular Probes, Inc.), fluorescent sterols including cholesteryl 4,4-difluoro-5,7- dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoate and cholesteryl 1- pyrenehexanoate, and fluorescently labeled proteins that interact specifically with lipid bilayer components such as the fluorescein derivative of annexin V (Caltag Antibody Co, Burlingame, CA).
  • fluorescent phospholipids such as nitrobenzoxadiazole g
  • the intracellular component of the plasma membrane is labeled with fluorescent molecules.
  • these molecules are the intracellular components of the trimeric G-protein receptor, adenylyl cyclase, and ionic transport proteins. These molecules can be labeled as a result of tight binding to a fluorescently labeled specific antibody or by the inco ⁇ oration of a fluorescent protein chimera that is comprised of a membrane-associated protein and the green fluorescent protein, and mutants thereof.
  • ligands that are transported into cells by receptor-mediated endocytosis are used to trace the dynamics of endosomal organelles.
  • labeled ligands include Bodipy FL-labeled low density lipoprotein complexes, tetramethylrhodamine transfenin analogs, and fluorescently labeled epidermal growth factor (Molecular Probes, Inc.)
  • fluorescently labeled primary or secondary antibodies (Sigma Chemical Co. St. Louis, MO; Molecular Probes, Inc. Eugene, OR; Caltag Antibody Co.) that specifically label endosomal ligands are used to mark the endosomal compartment in cells.
  • endosomes are fluorescently labeled in cells expressing protein chimeras formed by fusing a green fluorescent protein, or mutants thereof, with a receptor whose intemalization labels endosomes.
  • Chimeras of the EGF, transferrin, and low density lipoprotein receptors are examples of these molecules.
  • membrane permeant lysosome-specific luminescent reagents are used to label the lysosomal compartment of living and fixed cells. These reagents include the luminescent molecules neutral red, N-(3-((2,4- dinitrophenyl)amino)propyl)-N-(3-aminopropyl)methylamine, and the LysoTracker probes which report intralysosomal pH as well as the dynamic distribution of lysosomes (Molecular Probes, Inc.) In a second embodiment, antibodies against lysosomal antigens (Sigma
  • Chemical Co.; Molecular Probes, Inc.; Caltag Antibody Co. are used to label lysosomal components that are localized in specific lysosomal domains. Examples of these components are the degradative enzymes involved in cholesterol ester hydrolysis, membrane protein proteases, and nucleases as well as the ATP-driven lysosomal proton pump.
  • protein chimeras consisting of a lysosomal protein genetically fused to an intrinsically luminescent protein such as the green fluorescent protein, or mutants thereof, are used to label the lysosomal domain.
  • these components are the degradative enzymes involved in cholesterol ester hydrolysis, membrane protein proteases, and nucleases as well as the ATP-driven lysosomal proton pump.
  • cell permeant fluorescent dyes (Molecular Probes, Inc.) with a reactive group are reacted with living cells.
  • Reactive dyes including monobromobimane, 5-chloromethylfluorescein diacetate, carboxy fluorescein diacetate succinimidyl ester, and chloromethyl tetramethylrhodamine are examples of cell permeant fluorescent dyes that are used for long term labeling of the cytoplasm of cells.
  • polar tracer molecules such as Lucifer yellow and cascade blue-based fluorescent dyes (Molecular Probes, Inc.) are introduced into cells using bulk loading methods and are also used for cytoplasmic labeling.
  • antibodies against cytoplasmic components are used to fluorescently label the cytoplasm.
  • cytoplasmic antigens are many of the enzymes involved in intermediary metabolism. Enolase, phosphofractokinase, and acetyl-CoA dehydrogenase are examples of uniformly distributed cytoplasmic antigens.
  • protein chimeras consisting of a cytoplasmic protein genetically fused to an intrinsically luminescent protein such as the green fluorescent protein, or mutants thereof, are used to label the cytoplasm.
  • Fluorescent chimeras of uniformly distributed proteins are used to label the entire cytoplasmic domain. Examples of these proteins are many of the proteins involved in intermediary metabolism and include enolase, lactate dehydrogenase, and hexokinase.
  • antibodies against cytoplasmic antigens Sigma
  • cytoplasmic components that are localized in specific cytoplasmic sub-domains.
  • these components are the cytoskeletal proteins actin, tubulin, and cytokeratin.
  • a population of these proteins within cells is assembled into discrete stractures, which in this case, are fibrous. Fluorescence labeling of these proteins with antibody-based reagents therefore labels a specific sub-domain of the cytoplasm.
  • non-antibody-based fluorescently labeled molecules that interact strongly with cytoplasmic proteins are used to label specific cytoplasmic components.
  • cytoplasmic components include DNAse I (Molecular Probes, Inc.) Fluorescent analogs of this enzyme bind tightly and specifically to cytoplasmic actin, thus labeling a sub-domain of the cytoplasm.
  • fluorescent analogs of the mushroom toxin phalloidin or the drag paclitaxel are used to label components of the actin- and microtubule-cytoskeletons, respectively.
  • protein chimeras consisting of a cytoplasmic protein genetically fused to an intrinsically luminescent protein such as the green fluorescent protein, or mutants thereof, are used to label specific domains of the cytoplasm.
  • Fluorescent chimeras of highly localized proteins are used to label cytoplasmic sub- domains. Examples of these proteins are many of the proteins involved in regulating the cytoskeleton. They include the structural proteins actin, tubulin, and cytokeratin as well as the regulatory proteins microtubule associated protein 4 and ⁇ -actinin.
  • membrane permeant nucleic-acid-specific luminescent reagents are used to label the nucleus of living and fixed cells.
  • These reagents include cyanine-based dyes (e.g., TOTO ® , YOYO ® , and BOBOTM), phenanthidines and acri dines (e.g., ethidium bromide, propidium iodide, and acridine orange), indoles and imidazoles (e.g., Hoechst 33258, Hoechst 33342, and 4',6- diamidino-2-phenylindole), and other similar reagents (e.g., 7-aminoactinomycin D, hydroxystilbamidine, and the psoralens).
  • cyanine-based dyes e.g., TOTO ® , YOYO ® , and BOBOTM
  • phenanthidines and acri dines
  • antibodies against nuclear antigens are used to label nuclear components that are localized in specific nuclear domains. Examples of these components are the macromolecules involved in maintaining DNA structure and function. DNA, RNA, histones, DNA polymerase, RNA polymerase, lamins, and nuclear variants of cytoplasmic proteins such as actin are examples of nuclear antigens.
  • protein chimeras consisting of a nuclear protein genetically fused to an intrinsically luminescent protein such as the green fluorescent protein, or mutants thereof, are used to label the nuclear domain. Examples of these proteins are many of the proteins involved in maintaining DNA structure and function. Histones, DNA polymerase, RNA polymerase, lamins, and nuclear variants of cytoplasmic proteins such as actin are examples of nuclear proteins.
  • membrane permeant mitochondrial-specific luminescent reagents are used to label the mitochondria of living and fixed cells. These reagents include rhodamine 123, tetramethyl rosamine, JC-1, and the MitoTracker reactive dyes.
  • reagents include rhodamine 123, tetramethyl rosamine, JC-1, and the MitoTracker reactive dyes.
  • antibodies against mitochondrial antigens (Sigma Chemical Co.; Molecular Probes, Inc.; Caltag Antibody Co.) are used to label mitochondrial components that are localized in specific mitochondrial domains. Examples of these components are the macromolecules involved in maintaining mitochondrial DNA stracture and function.
  • mitochondrial antigens DNA, RNA, histones, DNA polymerase, RNA polymerase, and mitochondrial variants of cytoplasmic macromolecules such as mitochondrial tRNA and rRNA are examples mitochondrial antigens.
  • Other examples of mitochondrial antigens are the components of the oxidative phosphorylation system found in the mitochondria (e.g. , cytochrome c, cytochrome c oxidase, and succinate dehydrogenase).
  • protein chimeras consisting of a mitochondrial protein genetically fused to an intrinsically luminescent protein such as the green fluorescent protein, or mutants thereof, are used to label the mitochondrial domain.
  • these components are the macromolecules involved in maintaining mitochondrial DNA stracture and function. Examples include histones, DNA polymerase, RNA polymerase, and the components of the oxidative phosphorylation system found in the mitochondria (e.g., cytochrome c, cytochrome c oxidase, and succinate dehydrogenase).
  • membrane permeant endoplasmic reticulum-specific luminescent reagents are used to label the endoplasmic reticulum of living and fixed cells.
  • These reagents include short chain carbocyanine dyes (e.g., DiOC 6 and DiOC ), long chain carbocyanine dyes (e.g., DiIC ⁇ 6 and DiIC ⁇ 8 ), and luminescently labeled lectins such as concanavalin A.
  • antibodies against endoplasmic reticulum antigens include short chain carbocyanine dyes (e.g., DiOC 6 and DiOC ), long chain carbocyanine dyes (e.g., DiIC ⁇ 6 and DiIC ⁇ 8 ), and luminescently labeled lectins such as concanavalin A.
  • antibodies against endoplasmic reticulum antigens include short chain carbocyanine dyes (e.g., DiOC 6 and DiOC ), long chain carbocyanine dyes (e.g., DiIC
  • endoplasmic reticulum components that are localized in specific endoplasmic reticulum domains.
  • these components are the macromolecules involved in the fatty acid elongation systems, glucose-6-phosphatase, and HMG CoA-reductase.
  • protein chimeras consisting of a endoplasmic reticulum protein genetically fused to an intrinsically luminescent protein such as the green fluorescent protein, or mutants thereof, are used to label the endoplasmic reticulum domain.
  • these components are the macromolecules involved in the fatty acid elongation systems, glucose-6-phosphatase, and HMG CoA-reductase.
  • membrane permeant Golgi-specific luminescent reagents In one embodiment, membrane permeant Golgi-specific luminescent reagents
  • Molecular Probes, Inc. are used to label the Golgi of living and fixed cells. These reagents include luminescently labeled macromolecules such as wheat germ agglutinin and Brefeldin A as well as luminescently labeled ceramide.
  • antibodies against Golgi antigens are used to label Golgi components that are localized in specific Golgi domains. Examples of these components are N- acetylglucosamine phosphotransferase, Golgi-specific phosphodiesterase, and mannose-6-phosphate receptor protein.
  • protein chimeras consisting of a Golgi protein genetically fused to an intrinsically luminescent protein such as the green fluorescent protein, or mutants thereof, are used to label the Golgi domain.
  • these components are N-acetylglucosamine phosphotransferase, Golgi-specific phosphodiesterase, and mannose-6-phosphate receptor protein.
  • Wl ile many of the examples presented involve the measurement of single cellular processes, this is again is intended for pu ⁇ oses of illustration only.
  • Multiple parameter high-content screens can be produced by combining several single parameter screens into a multiparameter high-content screen or by adding cellular parameters to any existing high-content screen.
  • each example is described as being based on either live or fixed cells, each high-content screen can be designed to be used with both live and fixed cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La présente invention concerne des systèmes, procédés, cribles, et trousses pour un système d'analyse optique des cellules afin de déterminer rapidement la répartition, l'environnement, ou l'activité de molécules rapporteuses marquées en luminescence dans des cellules en vue du criblage parmi un grand nombre de composés ceux qui présentent un effet particulier sur des fonctions biologiques. L'invention concerne également la production de cellules contenant des molécules rapporteuses luminescentes dans un réseau de sites et le balayage de nombreuses cellules dans chacun des sites au moyen d'un système optique luminescent, convertissant l'information optique en données numériques, et utilisant les données numériques pour la détermination de la répartition, l'environnement ou l'activité des molécules rapporteuses marquées en luminescence dans les cellules.
EP00937548A 1999-05-14 2000-05-12 Un systeme de criblage a base de cellules Withdrawn EP1185863A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13419999P 1999-05-14 1999-05-14
US134199P 1999-05-14
US39896599A 1999-09-17 1999-09-17
US398965 1999-09-17
PCT/US2000/013208 WO2000070342A2 (fr) 1999-05-14 2000-05-12 Un systeme de criblage a base de cellules

Publications (1)

Publication Number Publication Date
EP1185863A2 true EP1185863A2 (fr) 2002-03-13

Family

ID=26832066

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00937548A Withdrawn EP1185863A2 (fr) 1999-05-14 2000-05-12 Un systeme de criblage a base de cellules

Country Status (3)

Country Link
EP (1) EP1185863A2 (fr)
AU (1) AU5269900A (fr)
WO (1) WO2000070342A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096038B2 (en) 2005-02-22 2015-08-04 Solutia, Inc. Low distortion interlayer

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989835A (en) 1997-02-27 1999-11-23 Cellomics, Inc. System for cell-based screening
US7853411B2 (en) 1997-02-27 2010-12-14 Cellomics, Inc. System for cell-based screening
US6759206B1 (en) 1997-02-27 2004-07-06 Cellomics, Inc. System for cell-based screening
WO2000079241A2 (fr) * 1999-06-21 2000-12-28 Cellomics, Inc. Systeme d'examen systematique de cellules
US6986993B1 (en) 1999-08-05 2006-01-17 Cellomics, Inc. System for cell-based screening
WO2001011341A2 (fr) * 1999-08-05 2001-02-15 Cellomics, Inc. Systeme criblage de cellules
WO2001042786A2 (fr) 1999-12-09 2001-06-14 Cellomics, Inc. Systeme de criblage a base de cellules
AU2002230415A1 (en) 2000-11-17 2002-05-27 Universal Imaging Corporation Rapidly changing dichroic beamsplitter
EP1368653B1 (fr) 2001-03-12 2013-01-23 Cellomics, Inc. Methodes pouvant augmenter la capacite d'essais de criblage cellulaire a grande densite
EP1499885B1 (fr) 2001-08-01 2009-10-21 Cellomics, Inc. Nouvelles proteines de fusion et analyses de detection de liaisons moleculaires
GB0203924D0 (en) * 2002-02-19 2002-04-03 Univ Bristol Screening method
WO2005026727A1 (fr) * 2003-09-15 2005-03-24 Pfizer Products Inc. Procedes de mesure de la proliferation du peroxysome et de l'induction liee au peroxysome
CN101484806A (zh) 2006-05-17 2009-07-15 协乐民公司 一种对组织进行自动分析的方法
AU2012229102B2 (en) 2011-03-17 2016-02-04 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
WO2023141189A2 (fr) * 2022-01-19 2023-07-27 Thrive Bioscience, Inc. Procédé et appareil d'imagerie de cellules permettant de compter des cellules, mesure de confluence et détection de plaque

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2282658C (fr) * 1997-02-27 2003-02-25 Cellomics, Inc. Systeme de criblage de cellules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0070342A3 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096038B2 (en) 2005-02-22 2015-08-04 Solutia, Inc. Low distortion interlayer

Also Published As

Publication number Publication date
WO2000070342A3 (fr) 2001-06-28
WO2000070342A2 (fr) 2000-11-23
AU5269900A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
EP1203214B1 (fr) Analyse de cellules par systeme optique
US8062856B2 (en) System for cell-based screening
US6716588B2 (en) System for cell-based screening
US6671624B1 (en) Machine readable storage media for detecting distribution of macromolecules between nucleus and cytoplasm in cells
US6727071B1 (en) System for cell-based screening
US7117098B1 (en) Machine-readable storage medium for analyzing distribution of macromolecules between the cell membrane and the cell cytoplasm
EP1131471B1 (fr) Systeme de criblage pour cellules
WO2000017643A9 (fr) Systeme de criblage cellulaire
US20040063162A1 (en) System for cell-based screening
US7853411B2 (en) System for cell-based screening
WO1998038490A9 (fr) Systeme de criblage de cellules
WO2000003246A2 (fr) Systeme destine a un criblage a base de cellules
WO2000050872A2 (fr) Systeme de criblage cellulaire
WO2001011341A2 (fr) Systeme criblage de cellules
EP1185863A2 (fr) Un systeme de criblage a base de cellules
WO2000079241A2 (fr) Systeme d'examen systematique de cellules
EP1439384B1 (fr) Système pour le criblage des cellules biologiques
MXPA01002684A (en) A system for cell-based screening
AU4604001A (en) A system for cell-based screening

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20011214

17Q First examination report despatched

Effective date: 20021007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021218